UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

~~(Mark One)~~

~~[X]~~

~~QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934~~

(Mark One)

☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ~~ended~~ ended: September 30, ~~2017.~~ 2023

~~[ ]~~

~~TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934~~

☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______ to _______.

Commission File Number:000-55453

ENDONOVO THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware		45-2552528
(State or other jurisdiction of		(I.R.S. Employer
incorporation or organization)		Identification No.)

6320 Canoga Avenue, 15th Floor, Woodland Hills, CA91367

(Address of principal executive offices, zip code)

(800)489-4774

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Securities Exchange Act: None

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ~~[X]~~ ☒ No ~~[ ]~~☐

Indicate by check mark whether the registrant has submitted electronically ~~and posted on its corporate Web site, if any,~~ every Interactive Data File required to be submitted ~~and posted~~ pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit ~~and post~~ such files). Yes ~~[X]~~ ☒ No ~~[ ]~~☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated ~~filer”~~filer,” “smaller reporting company,” and ~~“smaller reporting~~“emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ~~[ ]~~☐	Accelerated filer ~~[ ]~~☐

Non-accelerated filer ~~[ ]~~ ~~(do not check if smaller reporting company)~~ ☒	Smaller reporting company ~~[X]~~☒

	Emerging growth company ~~[X]~~☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ~~[X]~~☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ~~[ ]~~ ☐ No ~~[X]~~ ☒

As of ~~November 3, 2017,~~December 28, 2023, there were ~~3,274,764~~318,751,597 shares of common stock, $0.0001 par value issued and outstanding.

ENDONOVO THERAPEUTICS, INC.

TABLE OF CONTENTS

FORM 10-Q REPORT

September 30, ~~2017~~2023

		Page Number
PART I - FINANCIAL INFORMATION

Item 1.	Condensed Consolidated Financial ~~Statements.~~Statements (unaudited)	3
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of ~~Operations.~~Operations	1720
Item 3.	Quantitative and Qualitative Disclosures About Market ~~Risk.~~Risk	2223
Item 4.	Controls and ~~Procedures.~~Procedures	2223

PART II - OTHER INFORMATION

Item 1.	Legal ~~Proceedings.~~Proceedings	2324
Item 1A.	Risk ~~Factors.~~Factors	2324
Item 2.	Unregistered Sales of Equity Securities and Use of ~~Proceeds.~~Proceeds	24
Item 3.	Defaults Upon Senior Securities.	2425
Item 4.	Mine Safety Disclosures	2425
Item 5.	Other Information.	2425
Item 6.	Exhibits.	2425

SIGNATURES		26


~~SIGNATURES~~		25

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements.

Endonovo Therapeutics, Inc. ~~and Subsidiaries~~

Condensed Consolidated Balance Sheets

September 30, December 31,
2017 2016
(Unaudited) (Audited)

ASSETS
Current assets:
Cash $ 64,479 $ 55,533
Prepaid expenses and other current assets 91,000 247,321
Total current assets 155,479 302,854

Property Plant and Equipment, net 4,754 15,825

Total assets $ 160,233 $ 318,679

LIABILITIES AND SHAREHOLDERS' DEFICIT
Current Liabilities
Accounts payable and accrued expenses $ 3,238,237 $ 4,727,247
Short term advances 6,973 5,823
Notes payable, net of discounts of $920,773 as of September 30, 2017 and $1,145,849 as of December 31, 2016 2,549,445 1,878,107
Notes payable - related parties 170,000 170,000
Derivative liability 7,217,059 1,927,752
Current portion of long term loan 7,355 12,395

Total current liabilities 13,189,069 8,721,324

Long term loan - 4,221
Acquisition payable 155,000 155,000
Total liabilities 13,344,069 8,880,545
COMMITMENTS AND CONTINGENCIES
Shareholders' deficit
Super AA super voting preferred stock, $0.001 par value; 1,000,000 authorized and 5,000 and 1,000 issued and outstanding at September 30, 2017 and December 31, 2016 5 -
Series B convertible preferred stock, $0.0001 par value; 50,000 shares authorized, 0 shares issued and outstanding at September 30, 2017 and December 31, 2016 - -
Common stock, $.0001 par value; 500,000,000 shares authorized; 284,063,508 and 134,336,637 shares issued and outstanding as of September 30, 2017 and December 31, 2016 28,404 13,434
Additional paid-in capital 17,755,199 9,800,553
Stock subscriptions (14,070 ) (1,570 )
Accumulated deficit (30,953,374 ) (18,374,283 )
Total shareholders' deficit (13,183,836 ) (8,561,866 )
Total liabilities and shareholders' deficit $ 160,233 $ 318,679

	September 30, 2023			December 31, 2022
	(Unaudited)			(Audited)

ASSETS
Current assets:
Cash	$	0		$	98
Prepaid expenses and other current assets		35,504			15,724
Total current assets		35,504			15,822

Patents, net		780,260			1,265,444
Total assets	$	815,764		$	1,281,266

LIABILITIES AND SHAREHOLDERS’ DEFICIT
Current liabilities
Accounts payable and accrued liabilities	$	1,180,968		$	884,195
Accounts payable and accrued liabilities – related party		278,665			-
Accrued interest related to notes payable		4,417,039			3,542,650
Deferred compensation		4,229,029			3,918,788
Deferred compensation – related party		630,568			523,818
Notes payable, net of discounts of $28,210 and $10,587 as of September 30, 2023 and December 31, 2022		6,952,372			7,041,145
Notes payable – former related party		104,600			112,100
Derivative liability		5,902,829			17,359,064

Total current liabilities		23,696,070			33,381,760

Acquisition payable		79,825			79,825
Total liabilities		23,775,895			33,461,585
COMMITMENTS AND CONTINGENCIES, note 9		-			-

Shareholders’ deficit
Super AA super voting preferred stock, $0.001 par value; 1,000,000 authorized and 25,000 issued and outstanding at September 30, 2023 and December 31, 2022		25			25
Series B convertible preferred stock, $0.0001 par value; 50,000 shares authorized, 600 shares issued and outstanding at September 30, 2023 and December 31, 2022		1			1
Series C convertible preferred stock, $0.0001 par value; 8,000 shares authorized, 738 shares issued and outstanding at September 30, 2023 and December 31, 2022		-			-
Series D convertible preferred stock, $0.0001 par value; 20,000 shares authorized, 0 and 50 issued and outstanding at September 30, 2023 and December 31, 2022		-			-
Common stock, $0.0001 par value; 2,500,000,000 shares authorized; 318,751,597 and 213,227,538 shares issued and outstanding as of September 30, 2023 and December 31, 2022		27,940			21,322
Additional paid-in capital		43,644,063			42,919,086
Stock subscriptions receivable		(1,570	)		(1,570	)
Accumulated deficit		(66,630,590	)		(75,119,183	)
Total shareholders’ deficit		(22,960,131	)		(32,180,319	)
Total liabilities and shareholders’ deficit	$	815,764		$	1,281,266

See accompanying summary of accounting policies and notes to unaudited condensed consolidated financial statements.

Endonovo Therapeutics, Inc. ~~and Subsidiaries~~

Condensed Consolidated ~~Statement~~Statements of Operations

(Unaudited)

	Three Months Ended						Nine Months Ended
	September 30,						September 30,						Three Months Ended						Nine Months Ended
	2017			2016			2017			2016			September 30,						September 30,
													2023			2022			2023			2022

Revenue													$	1,520		$	10,960		$	134,260		$	13,892
Cost of revenue														827			4,027			4,823			5,124
Gross profit														693			6,933			129,437			8,768

Operating expenses	$	1,035,628		$	1,310,748		$	3,770,929		$	4,778,109			473,490			503,711			2,262,833			2,790,057
Loss from operations		(1,035,628	)		(1,310,748	)		(3,770,929	)		(4,778,109	)		(472,797	)		(496,778	)		(2,133,396	)		(2,781,289	)

Other income (expense)
Change in fair value of derivative liability		(4,544,656	)		46,997			(6,945,434	)		2,645,681			0			(56,213	)		11,445,466			(1,903,177	)
Gain (loss) on extinguishment of debt		(58,197	)		(42,507	)		2,175,459			(435,625	)
Settlement expense		(80,000	)		-			(80,000	)		-
Gain (loss) on settlement of debt														0			319,081			156,062			362,894
Other expense														(7,481	)		(30,879	)		(31,999	)		(208,879	)
Interest expense, net		(953,623	)		(912,583	)		(3,958,187	)		(2,007,788	)		(285,892	)		(338,571	)		(908,141	)		(1,012,249	)
Other income (expense)														(293,373	)		(106,582	)		10,661,388			(2,761,411	)
		(5,636,476	)		(908,093	)		(8,808,162	)		202,268

Loss before income taxes		(6,672,104	)		(2,218,841	)		(12,579,091	)		(4,575,841	)
Income (Loss) before income taxes														(766,170	)		(603,360	)		8,527,992			(5,542,700	)

Provision for income taxes		-			-			-			-			-			-			-			-

Net loss	$	(6,672,104	)	$	(2,218,841	)	$	(12,579,091	)	$	(4,575,841	)
Net Income (Loss)													$	(766,170	)	$	(603,360	)	$	8,527,992		$	(5,542,700	)

Basic and diluted loss per share	$	(0.03	)	$	(0.02	)	$	(0.06	)	$	(0.04	)
Basic Income (Loss) per share													$	(0.002	)	$	(0.00	)	$	0.03		$	(0.05	)
Diluted Loss per share													$	(0.00	)	$	(0.00	)	$	(0.00	)	$	(0.05	)
Weighted average common share outstanding:
Basic and diluted		263,535,090			123,138,397			220,353,026			113,649,351
Basic														298,391,943			153,599,760			276,355,156			122,537,266
Diluted														1,350,805,130			153,599,760			1,350,768,342			122,537,266

~~See accompanying summary of accounting polices and notes to unaudited condensed consolidated financial statements.~~

~~Endonovo Therapeutics, Inc. and Subsidiaries~~

~~Condensed Consolidated Statement of Cash Flows~~

~~(Unaudited)~~

Nine Months ended September 30,
2017 2016
Operating activities:
Net loss $ (12,579,091 ) $ (4,575,841 )
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation and amortization expense 11,070 11,876
Fair value of equity issued for services 1,410,071 2,402,736
Gain on extinguishment of debt (2,175,459 ) 545,905
Non-cash interest expense 2,465,912 779,045
Non-cash operating expenses on fees paid - 106,720
Amortization of note discount 1,467,888 826,063
Change in fair value of derivative liability 6,945,434 (2,645,681 )
Changes in assets and liabilities:
Other current assets 156,321 196,133
Accounts payable and accrued expenses 108,658 549,360
Net cash used in operating activities (2,189,196 ) (1,803,684 )

Investing activities:
Net cash used in investing activities - -

Financing activities:
Proceeds from the issuance of notes payable 1,562,000 1,051,228
Proceeds from short term advances 12,650 5,618
Repayments on short term advances (11,500 ) (15,300 )
Proceeds from issuance of preferred stock 5 -
Proceeds from issuance of common stock and units
740,250
1,055,829
Payment against long term loan (9,263 ) (8,989 )
Payment against notes payable (96,000 ) (156,500 )
Payment against notes payable- related parties - (75,000 )
Net cash provided by financing activities
2,198,142
1,856,886

Net increase in cash 8,946 53,202
Cash, beginning of year 55,533 41,473
Cash, end of period $ 64,479 $ 94,675

Supplemental disclosure of cash flow information:
Cash paid for interest $ 27,022 $ 25,486
Cash paid for income taxes $ - $ -

Non Cash Investing and Financing Activities:
Conversion of notes payable and accrued interest to common stock $ 1,108,321 $ 532,018
Common stock issued on settlement of debt $ 289,675 $ -
Notes payable and accrued interest exchanged for common stock units $ 66,367 $ -
Value of stock options granted in satisfaction of deferred compensation $ 1,467,311 $ -

~~See accompanying summary of accounting polices and notes to unaudited condensed consolidated financial statements.~~

~~Endonovo Therapeutics, Inc. and Subsidiaries~~

~~Condensed Consolidated Statement of Shareholders’ Deficit~~

~~(Unaudited)~~

Series AA Preferred Stock Series B Convertible Preferred Stock Common Stock Additional Paid-in Common Stock Subscription Retained Total Shareholder's
Shares Amount Shares Amount Shares Amount Capital Receivable Earnings Deficit

Balance December 31, 2016 1,000 $ - - $ - 134,336,637 $ 13,434 $ 9,800,553 $ (1,570 ) $ (18,374,283 ) $ (8,561,866 )

Private placement units issued for cash - - - - 28,830,028 2,882 737,368 (12,500 ) - 727,750
Preferred stock issued for cash 4,000 5 - - - - - - - 5
Shares issued for services - - - - 3,598,996 359 199,196 - - 199,555
Shares issued with lock-up agreements - - - - 126,618 13 7,517 - - 7,530
Shares issued for conversion of notes payable and accrued interest - - - - 106,110,372 10,610 3,977,803 - - 3,988,413
Private placement units issued for conversion of notes payable and accrued interest - - - - 3,370,041 337 66,029 - - 66,366
Shares issued related to debt extinguishment - - - - 1,565,816 156 86,838 - - 86,994
Shares issued for repayment of accrued liabiity - - - - 6,125,000 613 202,068 - - 202,681
Valuation of stock options issued for servces - - - - - - 1,139,403 - - 1,139,403
Valuation of warrants issued for services - - - - - - 71,113 - - 71,113
Valuation of stock options issued in exchange of deferred compensation - - - - - - 1,467,311 - - 1,467,311
Net loss for the period ended September 30, 2017 - - - - - - - - (12,579,091 ) (12,579,091 )
Balance September 30, 2017 5,000 $ 5 - $ - 284,063,508 $ 28,404 $ 17,755,199 $ (14,070 ) $ (30,953,374 ) $ (13,183,836 )

See accompanying summary of accounting policies and notes to unaudited condensed consolidated financial statements.

Endonovo Therapeutics, Inc.

Condensed Consolidated Statements of Cash Flows

(Unaudited)


	Nine Months ended September 30,
	2023			2022
Operating activities:
Net Income (Loss)	$	8,527,992		$	(5,542,700	)
Adjustments to reconcile net income (loss) to cash used in operating activities:
Amortization expense		485,185			485,184
Stock compensation expense		200,966			-
Fair value of equity issued for services		720,562			1,281,900
Loss (gain) on extinguishment of debt		(156,062	)		(362,894	)
Amortization of note discount and original issue discount		12,002			90,427
Change in fair value of derivative liability		(11,445,466	)		1,903,177
Changes in assets and liabilities:
Prepaid expenses and other current assets		9,052			7,975
Account payable and accrued liabilities (related and unrelated parties)		49,534			297,250
Accrued interest		908,141			921,822
Deferred compensation		283,731			464,562
Net cash used in operating activities		(404,363	)		(453,297	)

Financing activities:
Proceeds from the issuance of notes payable		195,000			400,000
Repayments on former related party of notes payable		(7,500	)		(9,500	)
Repayments of convertible debt in cash		(40,000	)		-
Proceeds from issuance of common stock and units, net		256,765			-
Net cash provided by financing activities		404,265			390,500

Net increase (decrease) in cash		(98	)		(62,797	)
Cash, beginning of year		98			85,936
Cash, end of period	$	0		$	23,139

Supplemental disclosure of cash flow information:
Cash paid for interest	$	-		$	-
Cash paid for income taxes	$	-		$	-

Non-Cash Investing and Financing Activities:
Conversion of notes payable and accrued interest to common stock	$	109,000		$	339,000
Conversion of Preferred C Stock to common stock	$	500		$	-
Issuance of common stock to settle debt	$	45,000		$	-
Debt discount from issuance of debt	$	32,875		$	44,098
Conversion of notes to common stock pursuant to settlement agreement	$	159,419		$	-

See accompanying summary of accounting policies and notes to unaudited condensed consolidated financial statements.

Endonovo Therapeutics, Inc.

Condensed Consolidated Statement of Shareholders’ Deficit

(Unaudited)

For three and nine months ended September 30, 2023


	Series AA Preferred Stock				Series B Convertible Preferred Stock				Series C Convertible Preferred Stock				Series D Convertible Preferred Stock					Common Stock				Additional Paid-in			Subscription			Accumulated			Total Shareholder’s
	Shares		Amount		Shares		Amount		Shares		Amount		Shares			Amount		Shares		Amount		Capital			Receivable			Deficit			Deficit
Balance December 31, 2022		25,000	$	25		600	$	1		738	$	-		50		$	-		213,227,538	$	21,322	$	42,919,086		$	(1,570	)	$	(75,119,183	)	$	(32,180,319	)

Shares issued for conversion of notes payable and accrued interest		-		-		-		-		-		-		-			-		10,900,000		1,090		107,910			-			-			109,000
Shares issued pursuant to make good provision																			1,507,277		151		24,719									24,870
Shares issued for settlement of debt		-		-		-		-		-		-		-			-		4,300,590		430		66,659			-			-			67,089
Issuance of common shares for services		-		-		-		-		-		-		-			-		12,850,000		1,285		171,665			-			-			172,950
Common stock issued for cash, net of fees		-		-		-		-		-		-		-			-		22,500,000		2,250		204,750			-			-			207,000
Shares issued for conversion of Preferred Series D to common shares		-		-		-		-		-		-		(50	)		-		5,000,000		500		(500	)		-			-			-
Inducement loss related to conversion of preferred stock		-		-		-		-		-		-		-			-		-		-		39,398			-			(39,398	)		-
Net income		-		-		-		-		-		-		-			-		-		-					-			7,230,502			7,230,502
Balance March 31, 2023		25,000	$	25		600	$	1		738	$	-		-		$	-		270,285,405	$	27,028	$	43,533,687		$	(1,570	)	$	(67,928,079	)	$	(24,368,908	)
Shares issued for conversion of deferred compensation		-		-		-		-		-		-		-			-		1,667,000		167		24,171			-			-			24,338
Issuance of commitment shares in connection with promissory notes		-		-		-		-		-		-		-			-		850,000		85		11,040			-			-			11,125
Stock-based compensation		-		-		-		-		-		-		-			-		-		-		6,025			-			-			6,025
Common Shares issued for services		-		-		-		-		-		-		-			-		1,000,000		100		15,900			-			-			16,000
Common stock issued for cash, net of fees		-		-		-		-		-		-		-			-		5,000,000		500		45,500			-			-			46,000
Net Income		-		-		-		-		-		-		-			-		-		-		-			-			2,063,660			2,063,660
Balance June 30, 2023		25,000	$	25		600	$	1		738	$	-		-		$	-		289,152,405	$	27,940	$	43,644,063		$	(1,570	)	$	(66,082,348	)	$	(22,411,889	)

Shares issued for conversion of deferred compensation		-		-		-		-		-		-		-			-		-		-		-			-			-			-
Issuance of commitment shares in connection with promissory notes		-		-		-		-		-		-		-			-		2,000,000		25		3,225			-			-			3,250
Stock-based compensation		-		-		-		-		-		-		-			-		350,000		35		4,515			-			-			4,550
Common Shares issued for services		-		-		-		-		-		-		-			-		8,000,000		-		-			-			-			-
Common stock issued for cash, net of fees		-		-		-		-		-		-		-			-		-		-		-			-			-			-
Net Income		-		-		-		-		-		-		-			-		-		-		-			-			(766,170	)		(766,170	)
Balance September 30, 2023		25,000	$	25		600	$	1		738	$	-		-		$	-		289,152,405	$	27,940	$	43,644,063		$	(1,570	)	$	(66,630,590	)	$	(22,960,131	)

For three and nine months ended September 30, 2022

	Series AA Preferred Stock				Series B Convertible Preferred Stock				Series C Convertible Preferred Stock				Series D Convertible Preferred Stock				Common Stock				Additional Paid-in		Subscription			Accumulated			Total Shareholder’s
	Shares		Amount		Shares		Amount		Shares		Amount		Shares		Amount		Shares		Amount		Capital		Receivable			Deficit			Deficit
Balance December 31, 2021		25,000	$	25		600	$	1		738	$	-		305	$	-		74,498,760	$	7,449	$	40,663,187	$	(1,570	)	$	(56,443,416	)	$	(15,774,324	)

Shares issued for conversion of notes payable and accrued interest		-		-		-		-		-		-		-		-		3,700,000		370		88,430		-			-			88,800
Common stock issued for settlement of debt																		2,428,777		243		45,904								46,147
Issuance of commitment shares in connection with promissory note		-		-		-		-		-		-		-		-		700,000		70		15,680		-			-			15,750
Net loss for the quarter ended March 31, 2022		-		-		-		-		-		-		-		-		-		-				-			(2,413,209	)		(2,413,209	)
Balance March 31, 2022		25,000	$	25		600	$	1		738	$	-		305	$	-		81,327,538	$	8,132	$	40,813,201	$	(1,570	)	$	(58,856,625	)	$	(18,036,836	)

Shares issued for conversion of notes payable and accrued interest		-		-		-		-		-		-		-		-		6,500,000		650		114,550		-			-			115,200
Issuance of commitment shares in connection with promissory note		-		-		-		-		-		-		-		-		350,000		35		5,698		-			-			5,733
Common Shares issued for services		-		-		-		-		-		-		-		-		62,250,000		6,225		1,275,675		-			-			1,281,900
Net loss		-		-		-		-		-		-		-		-		-		-		-		-			(2,526,131	)		(2,526,131	)
Balance June 30, 2022		25,000	$	25		600	$	1		738	$	-		305	$	-		150,427,538	$	15,042	$	42,209,124	$	(1,570	)	$	(61,382,756	)	$	(19,160,134	)
Balance		25,000	$	25		600	$	1		738	$	-		305	$	-		150,427,538	$	15,042	$	42,209,124	$	(1,570	)	$	(61,382,756	)	$	(19,160,134	)

Issuance of commitment shares in connection with promissory note		-		-		-		-		-		-		-		-		2,050,000		205		22,410		-			-			22,615
Common Shares issued for services		-		-		-		-		-		-		-		-		6,750,000		675		134,325		-			-			135,000
Net loss		-		-		-		-		-		-		-		-		-		-		-		-			(603,360	)		(603,360	)
Net Income (loss)		-		-		-		-		-		-		-		-		-		-		-		-			(603,360	)		(603,360	)
Balance September 30, 2022		25,000	$	25		600	$	1		738	$	-		305	$	-		159,227,538	$	15,922	$	42,365,859	$	(1,570	)	$	(61,986,116	)	$	(19,605,879	)
Balance		25,000	$	25		600	$	1		738	$	-		305	$	-		159,227,538	$	15,922	$	42,365,859	$	(1,570	)	$	(61,986,116	)	$	(19,605,879	)

See accompanying summary of accounting policies and notes to unaudited condensed consolidated financial statements.

Endonovo Therapeutics, Inc. ~~and Subsidiaries~~

Notes to Condensed Consolidated Financial Statements

Note 1 - Organization and Nature of Business

Endonovo Therapeutics, Inc. ~~and Subsidiaries (the~~(Endonovo or the “Company” ~~or “ETI”~~) is ~~primarily~~an innovative biotechnology company that has developed a bio-electronic approach to regenerative medicine. Endonovo is a growth stage company whose stock is publicly traded (OTCQB: ENDV).

The Company develops, manufactures, and distributes evolutionary medical devices focused on the rapid healing of wounds and reduction of pain, edema, and inflammation in the ~~business~~human body. The Company’s non-invasive bioelectric medical devices are designed to target inflammation, cardiovascular diseases, chronic kidney disease, and central nervous system disorders (“CNS” disorders).

The Company’s non-invasive Electroceutical® therapeutics device, SofPulse®, using pulsed short-wave radiofrequency at 27.12 MHz has been FDA-Cleared and CE Marked for the palliative treatment of ~~biomedical research~~soft tissue injuries and ~~development, particularly~~post-operative plain and edema, and has CMS National Coverage for the treatment of chronic wounds. The Company’s current portfolio of pre-clinical stage Electroceutical® therapeutics devices address chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD) and ischemic stroke.

Endonovo’s core mission is to transform the field of medicine by developing safe, wearable, non-invasive bioelectric medical devices that deliver the Company’s Electroceutical^® Therapy. Endonovo’s bioelectric Electroceutical^® devices harnesses bioelectricity to restore key electrochemical processes that initiate anti-inflammatory processes and growth factors in ~~regenerative medicine, which has included~~ the ~~development of its proprietary non-invasive electrocuetical device.~~ body necessary for healing to rapidly occur.

The Company ~~has historically been involved with intellectual property licensing and commercialization.~~intends to be structured into two separate divisions:

	■	A commercial stage developer primarily of non-invasive wearable Electroceuticals® therapeutic devices for pain relief, general wellness, and wound curatives with many of its products marketed under the SofPulse® brand name. This division will be controlled by Ira Weisberg, the Company’s President and Chief Commercial Officer.
	■	M&A division with a strategy of purchasing profitable companies, which will be managed by the Company’s current Chief Executive Officer.

Note 2 – Summary of significant accounting policies.

Basis of Presentation and Principles of Consolidation

The accompanying unaudited interim condensed consolidated financial statements have been presented in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and the instructions to Article 8 of Regulation S-X. Accordingly, the financial statements do not include all of the information and notes required by GAAP for complete financial statements. The accompanying consolidated condensed ~~consolidated financial statements~~balance sheet as of September 30, ~~2017~~2023, the consolidated statements of operations for the three and ~~2016~~nine months ended September 30, 2023 and 2022, the consolidated statements of cash flows for the nine months ended September 30, 2023 and 2022, and the consolidated statements of shareholders’ deficit for the three and nine months ended September 30, 2023 and 2022 are unaudited; however, in the opinion of management such interim ~~condensed~~ consolidated financial statements reflect all adjustments, consisting solely of normal recurring adjustments, necessary for a fair presentation of the results for the periods presented. The accompanying financial information should be read in conjunction with the financial statements and the notes thereto in the Company’s most recent Annual Report on Form 10-K, as filed with the Securities and Exchange Commission (the “SEC”) on April 17, 2023. The results of operations for the period presented are not necessarily indicative of the results that might be expected for future interim periods or for the full year.

Liquidity and Going Concern

The Company’s unaudited condensed consolidated financial statements ~~of the Company include the accounts of ETI and IPR as of March 14, 2012; Aviva as of April 2, 2013; and WeHealAnimals as of November 16, 2013. All significant intercompany accounts and transactions~~ are ~~eliminated in consolidation.~~

~~Going Concern~~

~~These accompanying consolidated financial statements have been~~ prepared ~~assuming the Company will continue as~~using GAAP applicable to a going concern, which contemplates the realization of assets and ~~the satisfaction~~liquidation of liabilities in the normal course of ~~business for the twelve month period following the date these consolidated financial statements are issued.~~business. The Company has ~~raised approximately $2,302,000 in debt~~not yet established an ongoing source of revenues sufficient to cover its operating costs and ~~equity financing for~~to continue as a going concern. The ability of the ~~period January 1, 2017~~Company to continue as a going concern is dependent on the Company’s ability to obtain adequate capital to fund operating losses until it becomes profitable.

As of September 30, ~~2017.~~2023, the Company had cash of approximately $0 and a working capital deficiency of approximately $23.1 million. During the nine months ended September 30, 2023, the Company used approximately $0.4 million of cash in its operation. The Company ~~is raising~~has incurred recurring losses resulting in an accumulated deficit of approximately $66.6 million as of September 30, 2023. These conditions raise substantial doubt as to its ability to continue as going concern within one year from issuance date of these unaudited consolidated financial statements.

Endonovo Therapeutics, Inc.

Notes to Condensed Consolidated Financial Statements (continued)

During the nine months ended September 30, 2023, the Company has raised $0.5 million in equity and debt financings. The Company will continue to raise additional capital through either debt ~~and~~or equity ~~securities in order~~financing to ~~continue the funding of~~fund its operations. However, there is no assurance that the Company can raise enough funds or generate sufficient revenues to pay its obligations as they become due, which raises substantial doubt about our ability to continue as a going concern.

On September 26, 2022, the Company entered into an asset purchase agreement with a Company, which is engaged in the business of providing and laying of concrete primarily for residential tract developers, pursuant to which the Company will acquire all of the assets and liabilities for approximately $25.2 million. The Company intends to raise the consideration through debt and equity financing. Such a transaction has not yet closed at the report date.

No adjustments have been made to the carrying value of assets or liabilities as a result of this uncertainty. To reduce the risk of not being able to continue as a going concern, management is commercializing its FDA cleared and CE marked products and has ~~implemented~~commenced implementing its business plan to materialize revenues from potential future license agreements, and ~~has initiated a private placement offering~~or diversifying its business activities with the potential acquisition of specialty construction company. The Company will continue to raise additional capital through the ~~sale~~issuance of fixed-rate conversion feature promissory notes.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Critical estimates include the assessment of impairment of finite lived intangibles, the valuation of the derivative liability, the valuation of warrants and stock options, and the valuation of deferred income tax assets. Management uses its historical records and knowledge of its ~~common stock,. In addition, management has a commitment~~business in making these estimates. Actual results could differ from ~~a current lender for a total of $2.7 million in the form of convertible notes. As of September 30, 2017, the~~these estimates.

Earnings (Loss) Per Share

The Company has received cash funding of $1,562,000 for $1,667,500 of convertible notes under this commitment. This commitment is subject to the Company not taking any variable financing from any other investor or lender. Although, uncertainty exists as to whether the Company will be able to generate enough cash from operations to fund the Company’s working capital needs or raise sufficient capital to meet the Company’s obligations as they become due, no adjustments have been made to the carrying value of assets or liabilities as a result of this uncertainty.

utilizes Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 260, “Earnings per Share.” Basic ~~and Diluted Income (Loss) per Share~~

~~Basic income~~earnings (loss) per share is computed ~~by dividing~~based on the ~~net income~~earnings (loss) attributable to common ~~stockholders for the period~~shareholders divided by the weighted average number of ~~common~~ shares outstanding ~~during~~for the ~~period.~~period excluding any dilutive effects of options, warrants, unvested share awards and convertible securities. Diluted ~~income~~earnings (loss) per common share is calculated similar to basic earnings (loss) per share except that the denominator is ~~computed by dividing the net income (loss) for the period by the weighted average number of~~increased to include additional common ~~and dilutive common equivalent shares outstanding during the period.~~

~~Endonovo Therapeutics, Inc. and Subsidiaries~~

~~Notes to Condensed Consolidated Financial Statements (continued)~~

~~Common equivalent shares, consisting of incremental common shares for the three and nine months ended September 30, 2017 issuable~~share equivalents available upon ~~the~~ exercise of stock ~~options,~~option, warrants, ~~and~~common shares issuable under convertible debt ~~have not~~and restricted stock using the treasury stock method. Dilutive common share equivalents include the dilutive effect of in-the-money share equivalents, which are calculated based on the average share price for each period using the treasury stock method, excluding any common share equivalents if their effect would be anti-dilutive. In periods in which a net loss has been ~~included in~~incurred, all potentially dilutive common shares are considered anti-dilutive and thus are excluded from the ~~diluted earnings per share~~calculation. Securities that are excluded from the calculation ~~for the three and nine months ended September 30, 2017 or 2016~~of weighted average dilutive common shares because their ~~effect is anti-dilutive.~~

~~Recently Issued Accounting Pronouncements~~

In August 2014, the FASB issued FASB ASU2014-15, Presentation of Financial Statements—Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. FASB ASU 2014-15 changes to the disclosure of uncertainties about an entity’s ability to continue as a going concern. These changes require an entity’s management to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that financial statements are issued. Substantial doubt is defined as an indication that it is probable that an entity will be unable to meet its obligations as they become due within one year after the date that financial statements are issued. If management has concluded that substantial doubt exists, then the following disclosures should be made in the financial statements: (i) principal conditions or events that raised the substantial doubt, (ii) management’s evaluation of the significance of those conditions or events in relation to the entity’s ability to meet its obligations, (iii) management’s plans that alleviated the initial substantial doubt or, if substantial doubt was not alleviated, management’s plans that are intended to at least mitigate the conditions or events that raise substantial doubt, and (iv) if the latter in (iii) is disclosed, an explicit statement that there is substantial doubt about the entity’s ability to continue as a going concern. These changes became effective for the Company for the 2016 annual period. Management has evaluated the impact of the adoption of these changes and has determined there will be no material impact on the consolidated financial statements. Subsequent to adoption, this guidance will need to be applied by management at the end of each annual period and interim period therein to determine what, if any, impact there will be on the consolidated financial statements in a given reporting period.

In April 2015, the FASB issued ASU No 2015-3, Simplifying the Presentation of Debt Issuance Costs. This update changes the presentation of debt issuance costs in the balance sheet. ASU 2015-03 requires debt issuance costs related to a recognized debt obligation to be presented in the balance sheet as a direct deduction from the carrying amount of the related debt liability rather than being presented as an asset. Amortization of debt issuance costs will continue to be reported as interest expense. In August 2015, the FASB issued ASU 2015-15, “Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements”. This ASU clarified guidance in ASC 2015-03 stating that the SEC staffinclusion would not object to a company presenting debt issuance costs related to a line-of-credit arrangement on the balance sheet as a deferred asset, regardless of whether there were any outstanding borrowings at period-end. This update is effective for annual and interim periods beginning after December 15, 2015, which required us to adopt these provisions in the first quarter of 2016. This update was applied on a retrospective basis, wherein the balance sheet of each period presented was adjusted to reflect the effects of applying the new guidance. The adoption of this guidance did not have ~~a material impact on our consolidated financial statements.~~

In November 2015, the FASB issued ASU No 2015-17, Income Taxes (Topic 740). The amendments in ASU 2015-17 change the requirements for the classification of deferred taxes on the balance sheet. Currently, GAAP requires an entity to separate deferred income tax liabilities and assets into current and noncurrent amounts in a classified statement of financial position. To simplify the presentation of deferred income taxes, the amendments in this ASU require that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. The pronouncement is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2016. Earlier application is permitted for all entities as of the beginning of an interim or annual reporting period. The Company has early adopted this pronouncement for the fiscal reporting period ended December 31, 2016, and has reclassified the presentation of deferred income taxes in the prior period to conform to the current year classification in the consolidated balance sheets. As a result of the Company having recognized a valuation reserve for the entire deferred tax liability balance at September 30, 2017 and December 31, 2016, there is no impact of the presentation of deferred income taxes in our financial statements.

~~Endonovo Therapeutics, Inc. and Subsidiaries~~

~~Notes to Condensed Consolidated Financial Statements (continued)~~

In January 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-01, Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. The update intends to enhance the reporting model for financial instruments to provide users of financial statements with more decision-useful information and addresses certain aspects of the recognition, measurement, presentation, and disclosure of financial instruments. The new standard affects all entities that hold financial assets or owe financial liabilities. For public business entities, the amendments in this Update are effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Management is evaluating the impact of the adoption of these changes will have on the consolidated financial statements.

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which supersedes existing guidance on accounting for leases in “Leases (Topic 840)” and generally requires all leases to be recognized in the consolidated balance sheet. ASU 2016-02 is effective for annual and interim reporting periods beginning after December 15, 2018; early adoption is permitted. The provisions of ASU 2016-02 are to be applied using a modified retrospective approach.

~~The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements.~~

~~Note 2 – Property, Plant and Equipment~~

~~The following is a summary of equipment, at cost, less accumulated depreciation at September 30, 2017 and December 31, 2016:~~

September 30, December 31,
2017 2016

Autos $ 64,458 $ 64,458
Medical equipment 5,000 5,000
Other equipment 8,774 8,774
78,232 78,232
Less accumulated depreciation 73,478 62,407
$ 4,754 $ 15,825

~~Depreciation expense~~been antidilutive for the nine months ended September 30, ~~2017~~2023, include stock options, warrants, and ~~2016 was $11,071~~notes payable.

The Company has 6,011,750 stock options to purchase an equivalent number of shares of common stock outstanding at September 30, 2023. The Company has 263,070 options and ~~$11,876, respectively. Repairs~~2,000 warrants to purchase common stock outstanding at September 30, 2022.

The components of basic and maintenance are charged to expense as incurred while improvements are capitalized. Upon the sale, retirement or disposal of fixed assets, the accounts are relieved of the cost and the related accumulated depreciation with any gain or loss recorded to the consolidated statements of operations.

~~Note 3 - Notes Payable and Long Term Loan~~

~~Notes Payable~~

~~During~~diluted income (loss) per share for the nine months ended September 30, ~~2017,~~2023 and 2022 were as follows:

Schedule of Earnings Per Share Basic and Diluted

	2023			2022
	Nine months ended September 30,
	2023			2022
Numerator:
Net income (loss) attributable to common shareholders	$	8,857,992		$	(5,542,700	)

Effect of dilutive securities
Convertible notes		(10,823,217	)		-
Net loss for diluted earnings per share	$	(2,295,225	)	$	(5,542,700	)
Denominator:
Weighted-average number of common shares outstanding during the period		276,355,156			55,303,026
Dilutive effect of convertible notes payable		1,074,413,187			-
Common stock and common stock equivalents used for diluted loss per share		1,350,768,342			55,303,026

The components of basic and diluted income (loss) per share for the three months ended September 30, 2023 and 2022 were as follows:

	2023			2022
	Three months ended September 30,
	2023			2022
Numerator:
Net income (loss) attributable to common shareholders	$	(766,170	)	$	(603,360	)

Effect of dilutive securities
Convertible notes		285,892			-
Net loss for diluted earnings per share	$	(480,278	)	$	(603,360	)
Denominator:
Weighted-average number of common shares outstanding during the period		298,391,943			153,599,760
Dilutive effect of convertible notes payable		1,074,413,187			-
Common stock and common stock equivalents used for diluted loss per share		1,372,805,130			153,599,760

Accounts Receivable

The Company ~~issued eleven Convertible Notes (“Variable Notes”) totaling $1,667,500 with original terms ranging from six months to one year with interest rates equal to 10%,~~uses the specific identification method for recording the provision for doubtful accounts, which was $0 as of September 30, 2023 and a variable conversion rate with a discount of 30% of the Company’s common stock based on the terms included in the Variable Notes. The Variable Notes contain a prepayment option, which enables the Company to prepay the note subsequent to issuance at a premium of 125%.December 31, 2022. Account receivables are written off when all collection attempts have failed.

Endonovo Therapeutics, Inc. ~~and Subsidiaries~~

Notes to Condensed Consolidated Financial Statements (continued)

~~During~~Newly Adopted Accounting Principles

The Company has evaluated all the ~~nine months ended September 30, 2017,~~recent accounting pronouncements and determined that there are no other accounting pronouncements that will have a material effect on the Company’s consolidated financial statements.

Note 3 - Revenue Recognition

Contracts with Customers

The Company adopted ASC 606, Revenue from Contracts with Customers effective January 1, 2019, using the modified retrospective method applied to those contracts which were not substantially completed as of January 1, 2019. These standards provide guidance on recognizing revenue, including a five-step model to determine when revenue recognition is appropriate. The standard requires that an ~~investor~~entity recognize revenue to depict the transfer of control of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.

The Company routinely plans on entering into contracts with customers that include general commercial terms and conditions, notification requirements for price increases, shipping terms and in most cases prices for the products and services that we offer. The Company’s performance obligations are established when a customer submits a purchase order notification (in writing, electronically or verbally) for goods and services, and we accept the order. The Company identified performance obligations as the delivery of the requested product or service in appropriate quantities and to the location specified in the ~~Company’s Variable Notes purchased from another holder~~customer’s contract and/or purchase order. The Company generally recognize revenue upon the satisfaction of these criteria when control of the ~~Company’s Variable Notes an aggregate of $920,000 principal and $39,570 of accrued interest with terms that extended~~product or service has been transferred to the ~~maturities to one-year and increased the interest rate from 6% to 10% and contains a prepayment option,~~customer at which ~~enables~~time, the Company has an unconditional right to ~~prepay~~receive payment. The Company’s sales and sale prices are final, and our prices are not affected by contingent events that could impact the ~~note subsequent~~transaction price.

Revenues for our SofPulse® product is typically recognized at the time the product is shipped, at which time the title passes to ~~issuance. As a result of this modification,~~the customer, and there are no further performance obligations. Royalty/licensing revenue is also recognized at one point in time, when the units are shipped.

In connection with offering products and services provided to the end user by third-party vendors, the Company ~~recognized~~reviews the relationship between us, the vendor, and the end user to assess whether revenue should be reported on a ~~gain~~gross or net basis. In asserting whether revenue should be reported on ~~debt extinguishment of $2,358,919 during the nine months ended September 30, 2017.~~

~~During the nine months ended September 30, 2017,~~a gross or net basis, the Company ~~entered into a settlement agreement with a holder of two $33,000 convertible promissory notes totaling $66,000 in principal and $11,400 accrued interest wherein~~considers whether the Company ~~repaid in full the~~acts as a principal and accrued interest balance with a payment of $90,000. In accordance with FASB ASC 470-50, Debt modifications and Extinguishments, the Company recognized a $58,115 gain on extinguishment of debt in connection with this settlement agreement.

~~The gross amount of all Variable Notes outstanding at September 30, 2017 is $2,495,315.~~

~~Notes payable to a related party~~ in the ~~aggregate amount of $170,000 were extended.~~transaction and control the goods and services used to fulfill the performance obligation(s) associated with the transaction.

~~As of September 30, 2017, other notes payable outstanding totaled $974,903, all of which are past maturity.~~

September 30, December 31,
2017 2016

Notes payable at beginning of period $ 3,193,956 $ 2,333,751
Notes payable issued 1,667,500 1,776,895
Default interest added to note payable - 62,500
Accrued interest payable added to note payable 39,570 -
Settlements on note payable - (55,000 )
Repayments of notes payable in cash (96,000 ) (241,500 )
Less amounts converted to stock (1,164,808 ) (682,690 )
Notes payable at end of period 3,640,218 3,193,956
Less debt discount (920,773 ) (1,145,849 )
$ 2,719,445 $ 2,048,107

Notes payable issued to related parties $ 170,000 $ 170,000
Notes payable issued to non-related parties $ 2,549,445 $ 1,878,107

~~The maturity dates on the notes payable are as follows:~~

Notes to
12 months ending, Related parties Non-related parties Total

September 30, 2018 $ 170,000 $ 3,470,218 $ 3,640,218
$ 170,000 $ 3,470,218 $ 3,640,218

Endonovo Therapeutics, Inc. ~~and Subsidiaries~~

Notes to Condensed Consolidated Financial Statements (continued)

~~Long Term Loan~~Sources of Revenue

The Company has ~~financed~~identified the following revenues by revenue source:

1.	Sales to plastic surgeons
2.	Sales to wound care facilities
3.	Sales to hospital
4.	Sales to other physicians
5.	Royalty fee from licensing, net

For the three and nine months ended September 30, 2023 and 2022, the sources of revenue were as follows:

Schedule of Source of Revenue

	2023		2022		2023		2022
	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022

Royalty/licensing, net	$	-	$	-	$	126,520	$	-
Direct sales- medical care providers, gross		1,520		10,960		7,740		13,892
Total sources of revenue	$	1,520	$	10,960	$	134,260	$	13,892

The royalty/licensing revenue recognized in the nine months ended September 30, 2023, resulted from specific transactions. No general patent rights were assigned to the distributor. The royalty / licensing revenue is recorded on a net basis as the Company was not considered the principal but an agent for accounting purposes. The royalty / licensing revenue, net includes an ongoing contract with a customer that has a total gross sales value of $300,000, for which the Company recognized net revenue of $126,520 based on 1,000 units delivered during the period ended September 30, 2023. The royalty/licensing revenue is recognized when the customer picks up the units from the Company’s vendor.

On January 25, 2023, the Company entered into a sales support services agreement with Pulse Therapeutic Technology (“PTT”), an entity controlled by a former related party, under which PTT has been selling SofPulse® on a nonexclusive basis. Pursuant to such agreement, the deferred compensation owed to this former related party has been fully extinguished for a total amount of approximately $118,000.

Warranty

Our general product warranties do not extend beyond an assurance that the product delivered will be consistent with stated specifications and do not include separate performance obligations.

Significant Judgments in the Application of the Guidance in ASC 606

There are no significant judgments associated with the satisfaction of our performance obligations. We generally satisfy performance obligations upon shipment of the product to the customer. This is consistent with the time in which the customer obtains control of the products. Performance obligations are also generally settled quickly after the purchase order acceptance, therefore the value of unsatisfied performance obligations at the end of any reporting period is generally immaterial.

We consider variable consideration in establishing the transaction price. Forms of variable consideration applicable to our arrangements include sales returns, rebates, volume-based bonuses, and prompt pay discounts. We use historical information along with an ~~automobile.~~ analysis of the expected value to properly calculate and to consider the need to constrain estimates of variable consideration. Such amounts are included as a reduction to revenue from the sale of products in the periods in which the related revenue is recognized and adjusted in future periods as necessary.

Practical Expedients

Our payment terms for sales direct to distributors are substantially less than the one-year collection period that falls within the practical expedient in determination of whether a significant financing component exists.

Endonovo Therapeutics, Inc.

Notes to Condensed Consolidated Financial Statements (continued)

Note 4 – Patents.

In December 2017, we acquired from Rio Grande Neurosciences, Inc. (RGN) a patent portfolio for $4,500,000. The earliest patents expire in 2024. The following is a summary of patents less accumulated amortization at September 30, 2023 and December 31, 2022:

Schedule of Patents

	September 30, 2023		December 31, 2022

Patents	$	4,500,000	$	4,500,000

Less accumulated amortization		3,719,740		3,234,556

Patents, net	$	780,260	$	1,265,444

Amortization expense associated with patents was $485,184 for the nine months ended September 30, 2023.

The estimated future amortization expense related to patents as of September 30, 2023, is as follows:

Schedule of Estimated Future Amortization Expense

Twelve Months Ending September 30,	Amount

2024	$	646,192
2025		134,068

Total	$	780,260

Note 5- Notes Payable

As of September 30, 2023, and December 31, 2022, the notes payable activity was as follows:

Schedule of Notes Payable

	September 30, 2023			December 31, 2022

Notes payable at beginning of period	$	7,163,832		$	7,256,930
Notes payable issued		195,000			465,000
Repayments of notes payable in cash		(40,000	)		(14,000	)
Settlement on note payable		(133,650	)		(163,826	)
Less amounts converted to stock		(100,000	)		(380,272	)
Notes payable at end of period		7,085,182			7,163,832
Less debt discount		(28,210	)		(10,587	)
Note payable, net	$	7,056,972		$	7,153,245

Notes payable issued to a former related party	$	104,600		$	112,100
Notes payable issued to non-related parties	$	6,952,372		$	7,041,145

The maturity dates on the ~~loan~~notes-payable are as follows:

Twelve months ending,
September 30, 2018 $ 7,355
$ 7,355

Current portion $ 7,355
Long term portion $ -

Schedule of Maturity Dates of Notes Payable

	Notes to
12 months ending,	Former related party		Non-related parties		Total

Past due	$	104,600	$	6,770,582	$	6,875,182
September 30, 2024		-		210,000		210,000
	$	104,600	$	6,948,082	$	7,085,182

Activity for the nine months ended September 30, 2023

Fixed rate notes

During the nine months ended September 30, 2023, the Company converted $100,000 in principal and $9,000 in accrued interest into 10,900,000 shares of common stock.

During the nine months ended September 30, 2023, the Company executed an amendment or allonges to three fixed rate notes to extend the maturity date in exchange for $20,000 payment to the current balance of one note and an aggregate of 1,000,000 shares of common stock to two noteholders as of September 30, 2023, and $2,500 in extension fee payable at the revised maturity date.

During the nine months ended September 30, 2023, the Company issued five fixed-rate notes for an aggregate amount of $195,000, which carry interest between 10% and 15% and with maturity ranging between one to nine (1 to 9) months from issuance.

Endonovo Therapeutics, Inc.

Notes to Condensed Consolidated Financial Statements (continued)

As of September 30, 2023, the Company has a total of twenty-four (24) fixed-rate notes, of which eighteen (18) have a make good provision for a total principal of $1,440,000 and approximately $338,403 in accrued interest. Balance of fixed-rate notes was $1,849,728 and $1,819,728 as of September 30, 2023, and December 31, 2022, respectively. Accrued interest on fixed-rate notes was approximately $429,500 and $310,960 as of September 30, 2023, and December 31, 2023, respectively.

Such provision will require the Company to issue additional shares to ensure that the investor can realize a profit of 15% or 18% reselling the conversion shares. The value of the make good provision was approximately $250,000 as of September 30, 2023 and is reported under Accounts payable and accrued liabilities in the condensed consolidated balance sheet as of June 30, 2023. In addition, certain fixed-rate notes include a prepayment provision, which entitles the holder to a 15% cash premium. The Company concluded that such provision was not deemed material and probable as of September 30, 2023.

Variable-rate notes

During the nine months ended September 30, 2023, the Company executed a settlement agreement with one investor to extinguish the remaining principal balance of a promissory note into 4,300,590 shares of common stock, which resulted in a gain from debt extinguishment of approximately $77,000.

Fixed Rate note (former related party)

Notes payable to a former related party in the aggregate amount of $104,600 were outstanding at September 30, 2023, which are past maturity date. The notes bear interest between 10% and 12% per annum. During the nine months ended September 30, 2023, the Company repaid $7,500 in principal amount to this former related party. Refer to Note 7- Related Party Transactions.

Activity for the nine months ended September 30, 2022

Fixed rates Notes

During the nine months ended September 30, 2022, the Company issued five (5) fixed rate promissory notes totaling $400,000 for funding of $400,000 with original terms of nine months and interest rates of 15% and 18%. The holder of the promissory note can convert the outstanding unpaid principal and accrued interest at a fixed conversion rate, subject to standard anti-dilution features, six-month after issuance date.

As of September 30, 2022, the Company has eighteen (18) fixed-rate promissory notes with an outstanding balance of $1,920,900, of which $1,045,900 are past maturity. As of September 30, 2022, the Company has a total of fourteen (14) fixed rate notes for total principal amount of $1,400,000 includes a make good shares provision. Such provision will require the Company to issue additional shares to ensure that the investor can realize a profit of 15% or 18% reselling the conversion shares. The Company accrued approximately $209,000 related to the make-good provision as the amount is probable and can be reasonably estimated pursuant to ASC 450 Contingencies. Such amount was presented as other expense in the condensed consolidated statements of operations.

During the nine months ended September 30, 2022, the Company converted $124,900 in accrued interest and $214,100 in principal balance into 16,950,000 shares of common stock.

Certain fixed-rate notes include a prepayment provision, which entitles the holder to a 15% or 18% premium upon cash redemption by the Company. The prepayment penalty approximates $243,000 as of September 30, 2022, but the Company determined that such liability is not probable as of September 30, 2022, pursuant to ASC 450 Contingencies.

Variable-rate notes

The gross amount of all convertible notes with variable conversion rates outstanding as of September 30, 2022, is $4,607,100, which are all past maturity. There has been no conversion of notes into the Company’s common stock during the three and nine months ended September 30, 2022.

Endonovo Therapeutics, Inc.

Notes to Condensed Consolidated Financial Statements (continued)

Note 46 - Shareholders’ Deficit

~~Increase in Authorized Shares~~

~~On January 17, 2017, an increase in authorized capital stock from 250,000,000 shares to 500,000,000 shares became effective.~~

~~Series B Convertible~~ Preferred Stock

At September 30, 2017, there are 50,000 shares of Series B Convertible Preferred Stock (“Series B”) which are authorized and convertible into a like amount of common shares. None of the Series B have been issued or are outstanding at September 30, 2017.

~~Common Stock~~

The Company has entered into consulting agreements with various consultants for service to be provided to the Company. The agreements stipulate a monthly fee and a certain number of shares that the consultant vests in over the term of the contract. The consultant is issued a prorated number of authorized 5,000,000 shares of ~~common~~preferred stock ~~at the beginning~~which have been designated as follows:

Schedule of the contract, which the consultant earns over a three-month period. At the anniversary of each quarter, the consultant is issued a new allotment of common stock during the first 3 years of engagement and discretionary bonuses. In accordance with ASC 505-50 – Equity-Based Payment to Non-Employees, the common stock shares issued to the consultant are valued upon their vesting, with interim estimates of value as appropriate during the vesting period. During the nine months ended September 30, 2017, the Company issued 3,598,996 shares of common stock with a value of $195,555 related to these consulting agreements.Preferred Stock

	Number of Shares Authorized		Number of Shares Outstanding at September 30, 2023		Par Value		Liquidation Value
Series AA		1,000,000		25,000	$	0.0010	$	-
Preferred Series B		50,000		600	$	0.0001	$	100
Preferred Series C		8,000		738	$	0.0001	$	1,000
Preferred Series D		20,000		-	$	0.0001	$	1,000
Undesignated		3,922,000		-		-		-

During the nine months ended September 30, 2017, the Company issued pursuant to two private placement offerings 32,200,069 shares of common stock and the same number of warrants for cash of $727,750 and conversion of notes and accrued interest in the amount of $66,367. The Company also issued 106,110,372 shares of common stock for the conversion of notes and accrued interest of $1,108,321, which resulted in a loss on debt extinguishment of $269,255 during the nine months ended September 30, 2017.

Also, during the nine months ended September 30, 2017, the Company issued 126,618 shares of common stock valued at $7,530 related to the extension of outstanding notes and lock-up agreements, 6,125,000 shares of common stock valued at $202,681 for partial repayment of a $175,000 accrued liability in connection with a variable note settlement agreement entered into in December 2016, and 1,565,816 shares of common stock valued at $86,994 for settlement of the principal and interest outstanding on two notes payable.

~~Endonovo Therapeutics, Inc. and Subsidiaries~~

~~Notes to Condensed Consolidated Financial Statements (continued)~~

Series AA Preferred Shares

On February 22, 2013, the Board of Directors of the Company authorized an amendment to the Company’s Articles of Incorporation, as amended (the “Articles of Incorporation”), in the form of a Certificate of Designation that authorized the issuance of up to one million ~~(1,000,000)~~(1,000,000) shares of a new series of preferred stock, par value ~~$0.0001~~$0.001 per share, designated “Series AA Super Voting Preferred Stock,” for which the board of ~~directors~~director established the rights, preferences and limitations thereof.

Each holder of outstanding shares of Series AA Super Voting Preferred Stock shall be entitled to one hundred thousand (100,000) votes for each share of Series AA Super Voting Preferred Stock held on the record date for the determination of stockholders entitled to vote at each meeting of stockholders of the Company. ~~During~~ The Series AA Super Voting Preferred Stockholders will receive no dividends nor any value on liquidation.

There was no activity during the ~~quarter~~nine months ended September 30, ~~2017, the Company issued 4,000~~2023. There were 25,000 shares of Series AA Preferred stock outstanding as of September 30, 2023 and December 31, 2022.

Series B Convertible Preferred Stock

On February 7, 2017, the Company filed a certificate of designation for 50,000 shares of Series B Convertible Preferred Stock designated as Series B (“Series B”) which are authorized and convertible, at the option of the holder, commencing six months from the date of issuance into common shares and warrants. For each share of Series B, the holder, on conversion, shall receive the stated value divided by 75% of the market price on the date of purchase of Series B and a three-year warrant exercisable into up to a like amount of common shares with an ~~officer~~exercise price of 150% of the market price as defined in the Certificate of Designation. Dividends shall be paid only if dividends on the Company’s issued and ~~director~~outstanding Common Stock are paid, and the amount paid to the Series B holder will be as though the conversion shares had been issued. Series B holders have no voting rights. Upon liquidation, the holder of Series B, shall be entitled to receive an amount equal to the stated value, $100 per share, plus any accrued and unpaid dividends thereon before any distribution is made to Series C Secured Redeemable Preferred Stock or common stockholders.

There was no activity during the nine months ended September 30, 2023. There were 600 shares of Series B outstanding as of September 30, 2023 and December 31, 2022.

Endonovo Therapeutics, Inc.

Notes to Condensed Consolidated Financial Statements (continued)

Series C Convertible Redeemable Preferred Stock

On December 22, 2017, the Company filed a certificate of designation for 8,000 shares of Series C Secured Redeemable Preferred Stock (“Series C”). Each share of the C Preferred is entitled to receive a $20 quarterly dividend commencing March 31, 2018, and each quarter thereafter and is to be redeemed for the stated value, $1,000 per share, plus accrued dividends in cash (i) at the Company’s option, commencing one year from issuance and (ii) mandatorily as of December 31, 2019. Management determined that the Series C should be classified as liability per the guidance in ASC 480 Distinguishing Liabilities from Equity as of December 31, 2019. On January 29, 2020, the Company filed the amended and restated certificate of designation fort its Series C Secured Redeemable Preferred Stock. The amendment changed the rights of the Series C by (a) removing the requirement to redeem the Series C, (b) removing the obligation to pay dividends on the Series C, (c) Allowing the holders of shares of Series C to convert the stated value of their shares into common stock of the Company ~~for $4. As~~at 75% of the closing price of such common stock on the day prior to the conversion. The C Preferred does not have any rights to vote with the common stock.

Upon liquidation, the holder of Series C, shall be entitled to receive an amount equal to the stated value, $1,000 per share, plus any accrued and unpaid dividends thereon before any distribution is made to common stockholders but after distributions are made to holders of Series B.

There was no activity during the nine months ended September 30, 2023. There were 738 shares of Series C outstanding, as of September 30, ~~2017, there were 5,000~~2023 and December 31, 2022

Series D Convertible Preferred Stock

On November 11, 2019, the Company filed a certificate of designation for 20,000 shares of Series AAD Convertible Preferred Stock ~~outstanding.~~designated as Series D (“Series D”), which are authorized and convertible, at the option of the holder, at any time from the date of issuance, into shares of common shares. On or prior to August 1, 2020, for each share of Series D, the holder, on conversion, shall receive a number of common shares equal to 0.01% of the Company’s issued and outstanding shares on conversion date and for conversion on or after August 2, 2020, the holder shall receive conversion shares as though the conversion date was August 1, 2020, with no further adjustments for issuances by the Company of common stock after August 1, 2020, except for stock split or reverse stock splits of the common stock. Management classified the Series D in permanent equity as of June 30, 2023.

~~Warrants~~The Series D holders have no voting rights. Upon liquidation, the holder of Series D, shall be entitled to receive an amount equal to the stated value, $1,000 per share, plus any accrued and unpaid dividends thereon before any distribution is made to common stockholders.

During the six months ended June 30, 2023, the Company issued 5,000,000 shares of common stock upon conversion of the remaining 50 shares of Series D preferred stock. The Company is also committed to providing additional shares of common stock if the holders of Series D do not realize a 15% profit on the resale of the conversion shares. As of June 30, 2023, and December 31, 2022, there were 0 and 50 shares of Series D outstanding, respectively.

Common Stock

Activity during the nine months ended September 30, 2023

During the nine months ended September 30, 2023, the Company issued 10,900,000 shares of common stock for the conversion of $109,000 of principal accrued interest from one note holder.

During the nine months ended September 30, 2023, the Company issued 1,507,277 shares of common stock pursuant to a make-good provision, which resulted in a loss on debt extinguishment of $24,870.

During the nine months ended September 30, 2023, the Company issued 4,300,590 shares of common stock pursuant to a debt settlement of aggregate principal of $113,650, resulting in a gain on debt extinguishment of approximately $77,000.

During the nine months ended September 30, 2023, the Company issued 1,667,000 shares of common stock pursuant to a deferred compensation settlement with a fair value of $24,338.

During the nine months ended September 30, 2023, the Company issued 5,967,590 shares of common stock pursuant to a debt settlement.

During the nine months ended September 30, ~~2017, in conjunction with~~2023, the ~~sale~~Company issued 43,800,000 shares of common stock ~~and issuance~~for services for a total fair value of ~~notes,~~$720,562

During the nine months ended September 30, 2023, the Company issued ~~three and five-year common stock purchase warrants to acquire up to 32,200,069~~5,000,000 shares of common ~~stock. These warrants have exercise prices ranging from $0.0165~~stock in exchange for 50 shares of Series D Preferred, which resulted in an inducement loss of $39,398 recorded as a deemed dividend in the shareholders’ deficit as of September 30, 2023.

During the nine months ended September 30, 2023, the Company issued 5 1/2 units or the equivalent of 27,500,000 shares of common stock pursuant to ~~$1.00 per share. In addition,~~a private placement for total net cash receipt of $253,000.

During the nine months ended September 30, 2023, the Company issued 1,850,000 commitment shares pursuant to executed securities purchase agreements with an estimated fair value of $25,625.

During the nine months ended September 30, 2023, the Company issued 1,000,000 shares for note extension and pursuant to executed allonges with an estimated fair value of $11,125.

Activity during the nine months ended September 30, 2017, the Company issued five-year common stock purchase warrants to acquire up to 1,100,678 shares of common stock valued at $71,113 related to consulting services received by the Company. These warrants have exercise prices ranging from $0.0961 to $0.2669 per share. The balance of all warrants outstanding as of September 30, 2017 is as follows:2022

Outstanding Warrants
Weighted Average
Exercise Price
Shares Per Share
Outstanding at January 1, 2017 9,494,940 $ 0.33
Granted 33,300,747 $ 0.24
Cancelled - $ -
Exercised - $ -
Outstanding at September 30, 2017 42,795,687 $ 0.26

Exercisable at September 30, 2017 42,795,687 $ 0.26

~~Stock Options~~

During the nine months ended September 30, ~~2017,~~2022, the Company ~~granted stock options to independent contractors exercisable into up to 25,272,305~~issued 16,950,000 shares of common stock ~~with exercise prices ranging from $0.0269 to $0.054 per share, lives ranging from three to ten years,~~for the conversion of $214,100 of principal notes and ~~cashless exercise rights and were valued at $1,139,403 using~~accrued interest in the ~~Black Scholes option pricing model. The stock options vested on grant and were expensed in full during~~amount of $124,900.

During the nine months ended September 30, ~~2017.~~2022, the Company issued 2,428,777 shares of common stock pursuant to a make-whole provision from an April 2021 debt settlement with one investor.

During the nine months ended September 30, 2022, the Company issued 3,100,000 shares of common stock as commitment shares in connection with promissory notes.

During the nine months ended September 30, 2022, the Company issued 62,250,000 shares of common stock for services for total fair value of $1,281,900.

Endonovo Therapeutics, Inc. ~~and Subsidiaries~~

Notes to Condensed Consolidated Financial Statements (continued)

In addition, during the nine months ended September 30, 2017, the Company issued stock options to independent contractors exercisable into up to 67,931,064 shares of common stock in exchange for the conversion of $1,467,311 of deferred compensation due to the independent contractors. These options have an exercise price of $0.0216 per share, a three-year life and cashless exercise rights. These options vested on grant. Stock Options

The balance of all stock options outstanding as of September 30, ~~2017~~2023, is as follows:

Weighted Average Weighted Average Aggregate
Exercise Price Remaining Contractual Intrinsic
Options Per Share Term (years) Value
Outstanding at January 1, 2017 - $ -
Granted 93,203,369 $ 0.029
Cancelled - $ -
Exercised - $ -
Outstanding at September 30, 2017 93,203,369 $ 0.029 4.29 $ 2,674,937

Exercisable at September 30, 2017 93,203,369 $ 0.029 4.29 $ 2,674,937

~~The following assumptions were used at September 30, 2017 to value the stock options using the Black Scholes option pricing model.~~Schedule of Stock Options Outstanding

				Weighted Average		Weighted Average Remaining		Aggregate
				Exercise Price		Contractual		Intrinsic
	Options			Per Share		Term (years)		Value
Outstanding at December 31, 2022		3,012,410		$	0.22		3.40		31,200
Granted		3,000,000		$	0.01		-
Cancelled		(660	)	$	11.60		-
Exercised		-		$	-		-
Outstanding at September 30, 2023		6,011,750		$	0.12		3.06	$	-

Exercisable at September 30, 2023		1,011,750		$	0.64		1.83	$	-

		~~Nine months ended~~
		~~September 30, 2017~~

~~Expected term~~		~~1.5 - 5 years~~
~~Exercise price~~		~~$0.0216 - $0.054~~
~~Expected volatility~~		~~184% - 190%~~
~~Expected dividends~~		~~None~~
~~Risk-free interest rate~~		~~1.23% - 1.79%~~
~~Forfeitures~~		~~None~~

~~Note 5 – Related Party Transactions~~

~~One officer and executive of the Company has entered into note payable agreement with the Company. The balance of notes payable from related parties at September 30, 2017 is $170,000.~~

~~As of September 30, 2017 and December 31, 2016, the balance of two executive officers and the operations manager deferred~~Share-based compensation ~~is approximately $1,155,794 and $1,861,327, respectively. During~~expenses for the nine months ended September 30, ~~2017, these individuals converted~~2023 and 2022, totaled approximately $6,000 and $0, respectively. The remaining stock-based compensation to be recognized is approximately $36,000, which will be recognized over 2.5 years.

Warrants

The balance of all warrants outstanding as of September 30, 2023, is as follows:

Schedule of Warrants Outstanding

	Outstanding Warrants
				Weighted Average		Weighted Average Remaining
				Exercise Price		Contractual
	Shares			Per Share		Term (years)
Outstanding at December 31, 2022		2,000		$	50.0		0.22
Granted		-		$	-		-
Cancelled		(2,000	)	$	50.0		-
Exercised		-		$	-
Outstanding at September 30, 2023		-		$	-		-

Exercisable at September 30, 2023		-		$	-		-

Endonovo Therapeutics, Inc.

Notes to Condensed Consolidated Financial Statements (continued)

Note 7 – Related Party and former related parties Transactions.

One executive officer of the Company has agreed to defer a ~~total~~portion of ~~$660,000~~his compensation until cash flow improves. As of September 30, 2023, the balance of the deferred compensation was $630,568, which reflects $225,000 accrual of deferred compensation ~~into three-year stock options exercisable into up to 30,555,555~~and $118,250 of cash repayment of deferred compensation during the nine months ended September 30, 2023.

As of September 30, 2023, the Company issued for the issuance of 20,000,000 shares of the Company’s common stock ~~at an exercise price~~with a fair value of ~~$0.0216 per share.~~$282,000. Such balance is reported under accounts payable and accrued liabilities related party in the condensed consolidated balance sheet as of September 30, 2023.

One former executive of the Company has agreed to defer a portion of his compensation until cash flow improves. As of September 30, 2023, the balance of his deferred compensation was $632,257. No activity occurred during the nine months ended September 30, 2023.

From time-to-time ~~executive officers and the operations manager~~officer of the Company advance monies to the Company to cover costs. The balance of short-term advances due to one officer of the Company at September 30, 2023, was $5,340 and is included in the Company’s accounts payable and accrued liabilities balance as of September 30, 2023. During the nine months ended September 30, ~~2017, officers~~2023, the Company’s executive officer advanced ~~$12,650~~an aggregate amount of ~~funds~~$5,215 for corporate expenses, and $2,500 was repaid back as of September 30, 2023.

As of September 30, 2023, notes payable remained outstanding to the ~~Company of which $11,500 were repaid during the period. The balance of short-term advances due to executive officers~~former President of the Company, atin the amount of $104,600. As of September 30, ~~2017 is $6,973.~~

~~Endonovo Therapeutics, Inc.~~2023, accrued interests on these notes payable totaled approximately $88,045, and ~~Subsidiaries~~

~~Notes to Condensed Consolidated Financial Statements (continued)~~

~~During~~are included in accrued expenses on the ~~quarter ended September 30, 2017, 4,000 shares of Series AA Preferred Stock was issued to an officer and director of the Company for $4.~~condensed consolidated balance sheets.

Note 68 – Fair Value Measurements

The Company ~~has~~ issued Variable Debentures, which contained variable conversion rates based on unknown future prices of the Company’s common stock. This results in a conversion feature. The Company measures the conversion feature using the Black Scholes option pricing model using the following assumptions:

Three months ended September 30, Nine months ended September 30,
2017 2016 2017 2016
Expected term .01 months - 1 year 1 month - 1 year .01 months - 1 years 1 month - 2.2 years
Exercise price $0.0130-$0.0182 $0.0690-$0.1051 $0.0085-$0.0385 $0.0645-$0.28
Expected volatility 189%-200% 255%-276% 189%-201% 220%-276%
Expected dividends None None None None
Risk-free interest rate 1.05% to 1.31% 0.52% to 0.59% 1.03% to 1.31% 0.45% to 1.06%
Forfeitures None None None None

~~The time period over which the Company will be required to evaluate the fair value~~Schedule of ~~the conversion feature is eight to twenty-four months or conversion.~~Conversion Feature Using Black Scholes Option Pricing Model

		Nine months ended September 30,
		2023			2022

Expected term		1 month			1 month
Exercise price	$	0.0066-$0.0151		$	0.004 – $0.015
Expected volatility		154%-158	%		152%-169	%
Expected dividends		None			None
Risk-free interest rate		4.64%-5.40	%		1.63% to 2.80	%
Forfeitures		None			None

The assumptions used in determining fair value represent management’s best estimates, but these estimates involve inherent uncertainties and the application of management’s judgment. As a result, if factors change, including changes in the market value of the Company’s common stock, managements’ assessment, or significant fluctuations in the volatility of the trading market for the Company’s common stock, the Company’s fair value estimates could be materially different in the future.

The Company computes the fair value of the derivative liability at each reporting period and the change in the fair value is recorded as non-cash expense or ~~non-cash~~ income. The key component in the value of the derivative liability is the Company’s stock price, which is subject to significant fluctuation and is not under its control. The resulting effect on net ~~loss~~income (loss) is therefore subject to significant fluctuation and will continue to be so until the Company’s ~~Variable Debentures,~~variable debentures, which the convertible feature is associated with, are converted into common stock or paid in full ~~with~~in cash. Assuming all other fair value inputs remain constant, the Company will record non-cash expense when its stock price increases and non-cash income when its stock price decreases. Company will perform valuation of derivative liabilities as a part of its 2023 10-K filing.

Endonovo Therapeutics, Inc. ~~and Subsidiaries~~

Notes to Condensed Consolidated Financial Statements (continued)

The following table presents changes in the liabilities with significant unobservable inputs (level 3) for the nine months ended September 30, ~~2017:~~2023:

Derivative
Liability
Balance December 31, 2016 $ 1,927,752

Issuance of convertible debt 5,781,056
Settlements by debt extinguishment (7,437,183 )
Change in estimated fair value 6,945,434

Balance September 30, 2017 $ 7,217,059

Schedule of Fair Value of Derivative Liability

	Derivative
	Liability
Balance December 31, 2022	$	17,359,064

Settlement debt		(10,769	)
Change in estimated fair value		(11,445,466	)

Balance September 30, 2023	$	5,902,829

Accounting guidance on fair value measurements and disclosures defines fair value, establishes a framework for measuring the fair value of assets and liabilities using a hierarchy system, and defines required disclosures. It clarifies that fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the market in which the reporting entity transacts business.

The ~~Company's~~Company’s balance sheet contains derivative ~~and warrant~~ liabilities that are recorded at fair value on a recurring basis. The three-level valuation hierarchy for disclosure of fair value is as follows:

Level 1: uses quoted market prices in active markets for identical assets or liabilities.

Level 2: uses observable market-based inputs or unobservable inputs that are corroborated by market data.

Level 3: uses unobservable inputs that are not corroborated by market data.

The fair value of the Company’s recorded derivative liability is determined based on unobservable inputs that are not corroborated by market data, which require a Level 3 classification. A Black Scholes option pricing model was used to determine the fair value. The Company records derivative liability on the condensed consolidated balance sheets at fair value with changes in fair value recorded in the condensed consolidated statements of operation.

~~Endonovo Therapeutics, Inc. and Subsidiaries~~

~~Notes to Condensed Consolidated Financial Statements (continued)~~

The following table presents balances in the liabilities with significant unobservable inputs (Level 3) atas of September 30, ~~2017:~~2023:

Fair Value Measurements Using
Quoted Prices in Significant Other Significant
Active Markets for Observable Unobservable
Identical Assets Inputs Inputs
(Level 1) (Level 2) (Level 3) Total

As of September 30, 2017
Derivative liability $ - $ - $ 7,217,059 $ 7,217,059
Total $ - $ - $ 7,217,059 $ 7,217,059

Schedule of Liabilities Significant Unobservable Inputs

		Fair Value Measurements Using
		Quoted Prices in
		Active Markets for	Significant Other		Significant
		Identical Assets	Observable Inputs		Unobservable Inputs
		(Level 1)	(Level 2)		(Level 3)		Total

As of September 30, 2023
Derivative liability	$	-	$	-	$	5,902,829	$	5,902,829
Total	$	-	$	-	$	5,902,829	$	5,902,829

Endonovo Therapeutics, Inc.

Notes to Condensed Consolidated Financial Statements (continued)

Note 79 – Commitments and Contingencies

Legal Matters

The Company ~~may become involved in various~~is subject to certain legal proceedings, which it considers routine to its business activities. As of September 30, 2023, the Company believes, after consultation with legal counsel, that the ultimate outcome of such legal proceedings, whether individually or in the ~~normal course~~aggregate, is not likely to have a material adverse effect on the Company’s financial position, results of ~~business.~~operations or liquidity.

OnNote 10 – Concentrations.

Sales

During the nine months ended September ~~19, 2017,~~30, 2023, we had one significant customer, which accounted for approximately 100% of sales. In addition, the Company ~~entered into~~generated all of its royalty/licensing revenue from one former related party.

Supplier

We also have a ~~Settlement Agreement with Kodiak Capital Group, LLC~~single source for ~~$80,000 relative to the 2015 EPA Agreement.~~our bioelectric medical devices, which account for 100% of our sales. The interruption of products provided by this supplier would adversely affect our business and financial condition unless an alternative source of products could be found.

Note 811 – Subsequent Events

~~Subsequent~~Management has evaluated events that have occurred subsequent to ~~September 30, 2017, an aggregate~~the date of ~~74,026 shares of restricted common stock~~these consolidated condensed financial statements and has determined that no such reportable subsequent events exist through the date the financial statements were issued ~~for services.~~in accordance with FASB ASC Topic 855, “Subsequent Events.”

Subsequent to September 30, 2017, the Company issued 10,160,435 shares of its restricted common stock and 9,697,473 warrants pursuant to a Private Placement Memorandum and private offerings for $429,990 in cash and $30,000 of converted notes.

Subsequent to September 30, 2017, an aggregate of 10,320,197 shares of restricted common stock were issued on the conversion of $160,000 of principal and $7,600 of accrued interest pursuant to one Variable Note.

~~Subsequent to September 30, 2017, an aggregate of 252,676 shares of restricted common stock were issued pursuant to leak out agreements.~~

Subsequent to September 30, 2017, the Company cancelled 196,078 shares of restricted common stock priced at $12,500 previously issued under a subscription agreement and 196,078 warrants to purchase the Company’s common stock.

~~Subsequent to September 30, 2017, the Company received $195,000 of funding in connection with $210,000 of convertible notes issued.~~

Subsequent to September 30, 2017, the Company issued a final tranche of 600,000 shares as full repayment on the $175,000 accrued liability in connection with a variable note settlement agreement entered into in December 2016.

~~As a result of these issuances the total number of shares outstanding is 305,274,764.~~

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Cautionary Notice Regarding Forward Looking Statements

The information contained in Item 2 contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Actual results may materially differ from those projected in the forward-looking statements as a result of certain risks and uncertainties set forth in this report. Although management believes that the assumptions made and expectations reflected in the forward-looking statements are reasonable, there is no assurance that the underlying assumptions will, in fact, prove to be correct or that actual results will not be different from expectations expressed in this report.

This filing contains a number of forward-looking statements which reflect management’s current views and expectations with respect to our business, strategies, products, future results and events, and financial performance. All statements made in this filing other than statements of historical fact, including statements addressing operating performance, events, or developments which management expects or anticipates will or may occur in the future, including statements related to distributor channels, volume growth, revenues, profitability, new products, adequacy of funds from operations, statements expressing general optimism about future operating results, and non-historical information, are forward looking statements. In particular, the words “believe,” “expect,” “intend,” “anticipate,” “estimate,” “may,” and variations of such words, and similar expressions identify forward-looking statements, but are not the exclusive means of identifying such statements, and their absence does not mean that the statement is not forward-looking. These forward-looking statements are subject to certain risks and uncertainties, including those discussed below. Our actual results, performance or achievements could differ materially from historical results as well as those expressed in, anticipated, or implied by these forward-looking statements. We do not undertake any obligation to revise these forward-looking statements to reflect any future events or circumstances.

Readers should not place undue reliance on these forward-looking statements, which are based on management’s current expectations and projections about future events, are not guarantees of future performance, are subject to risks, uncertainties and assumptions (including those described below), and apply only as of the date of this filing. Our actual results, performance or achievements could differ materially from the results expressed in, or implied by, these forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Overview

Endonovo Therapeutics, Inc. ~~(the~~(Endonovo or the “Company” ~~or “ETI”~~) ~~operates~~is an innovative biotechnology company that has developed a bio-electronic approach to regenerative medicine. Endonovo is a growth stage company whose stock is publicly traded (OTCQB: ENDV).

The Company develops, manufactures and distributes evolutionary medical devices focused on the rapid healing of wounds and reduction of pain, edema and inflammation in ~~two business segments: (1) intellectual property licensing~~the human body. The Company’s non-invasive bioelectric medical devices are designed to target inflammation, cardiovascular diseases, chronic kidney disease, and ~~commercialization;~~central nervous system disorders (“CNS” disorders).

The Company’s non-invasive Electroceutical® therapeutics device, SofPulse®, using pulsed short-wave radiofrequency at 27.12 MHz has been FDA-Cleared and ~~(2) biomedical research~~CE Marked for the palliative treatment of soft tissue injuries and ~~development which~~post-operative plain and edema, and has ~~included development~~CMS National Coverage for the treatment of ~~its proprietary~~chronic wounds. The Company’s current portfolio of pre-clinical stage Electroceutical® therapeutics devices address chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD) and ischemic stroke.

Endonovo’s core mission is to transform the field of medicine by developing safe, wearable, non-invasive ~~electrocuetical device.~~bioelectric medical devices that deliver the Company’s Electroceutical^® Therapy. Endonovo’s bioelectric Electroceutical^® devices harnesses bioelectricity to restore key electrochemical processes that initiate anti-inflammatory processes and growth factors in the body necessary for healing to rapidly occur.

~~Our present primary focus is the development, patenting and regulatory approval of our biomedical proprietary technology.~~

Going Concern

Our independent registered auditors included an explanatory paragraph in their opinion on our consolidated financial statements as of and for the fiscal year ended December 31, ~~2016~~2022, that states that our ongoing losses and lack of resources ~~causes substantial~~cause reasonable doubt about our ability to continue as a going concern.

Critical Accounting Policies

A summary of our significant accounting policies is included in Note 1 of the “Notes to the Consolidated Financial Statements,” contained in our Form 10-K for the year ended December 31, 2022. Management believes that the consistent application of these policies enables us to provide users of the financial statements with useful and ~~Estimates~~

~~We prepare~~reliable information about our operating results and financial condition. The summary condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the U.S. ~~(U.S. GAAP). In doing so, we have~~, which require us to make estimates and ~~assumptions that affect~~assumptions. We did not experience any significant changes during the nine months ended September 30, 2023, in any of our reported amounts of assets, liabilities, revenues, and expenses, as well as related disclosure of contingent assets and liabilities. In some cases, we could reasonably have used different accounting policies and estimates. In some cases, changes in the accounting estimates are reasonably likely to occur from period to period. Accordingly, actual results could differ materially from our estimates. To the extent that there are material differences between these estimates and actual results, our financial condition or results of operations will be affected. We base our estimates on past experience and other assumptions that we believe are reasonable under the circumstances, and we evaluate these estimates on an ongoing basis. We refer to accounting estimates of this type as critical accounting policies from those contained in our Form 10-K for the year ended December 31, 2022.

New Accounting Pronouncements

See Note 1 of Notes to Condensed Consolidated Financial Statements for further discussion of new accounting standards that have been adopted or are being evaluated for future adoption.

Results of Operations

Nine Months ended September 30, 2023, and ~~estimates,~~2022:

	Nine Months Ended September 30,						Favorable
	2023			2022			(Unfavorable)		%

Revenue	$	134,260		$	13,892		$	120,368		866	%
Cost of revenue		4,823			5,124			301		6	%
Gross profit		129,437			8,768			120,669		1,376	%

Operating expenses		2,262,833			2,790,057			527,224		19	%

Loss from operations		(2,133,396	)		(2,781,289	)		647,893		23	%

Other income (expense)		10,661,388			(2,761,411	)		13,422,799		486	%

Net loss	$	8,527,992		$	(5,542,700	)	$	14,070,692		254	%

Revenue

Revenue of the Company’s SofPulse® product during the nine months ended September 30, 2023, was $134,260, an increase of $120,368, or 44%, compared to $13,892 for the nine months ended September 30, 2022.

We anticipate that revenue will increase in future periods as the roll out of the SofPulse® product continues. The Company is looking to partner with global participants in the medical device market to spur its expansion. The Company expects such investment alternatives to include partnerships, joint ventures, distribution, and licensing agreements for the PEMF medical technology. The Company is also looking to expand on current initiatives with the Department of Defense, the Department of Veterans Affairs, and other surgical and pain management markets.

During the nine months ended September 30, 2023, the Company also recognized $126,520 in royalty/licensing revenue from a former related party.

Cost of Revenue

Cost of revenue during the nine months ended September 30, 2023, was $4,823, a decrease of $301 or 6% compared to $5,124 for the nine months ended September 30, 2022. Cost of revenue is recognized on those sales recorded as gross for which we ~~discuss further below.~~

~~Use of estimates~~

Inare the opinion of management, the accompanying condensed consolidated balance sheets and related interim statements of operations, cash flows, and shareholders' deficits include all adjustments, consisting only of normal recurring items, necessary for their fair presentation in conformity with accounting principles generally acceptedprincipal in the ~~United States~~transaction as opposed to net sales which reflect no cost of ~~America (“U.S. GAAP”). Preparing financial statements requires management~~revenue. It is anticipated that cost of revenue will increase in future quarters as the roll out of the SofPulse® product continues.

Operating Expenses

Operating expenses decreased by $527,224 or 19%, to ~~make estimates and assumptions that affect~~$2,262,833 for the ~~reported amounts~~nine months ended September 30, 2023, compared to $2,790,057 for the nine months ended September 30, 2022. This change was due primarily due a decrease in stock-based compensation expense by approximately $603,600.

Other Expense/Income

Other income for the nine months ended September 30, 2023, was $10,661,388 compared to an expense of ~~assets, liabilities, revenue, and expenses. The significant estimates were made~~$2,761,411 for the nine months ended September 30, 2022. This change was due primarily to a decrease in the fair value of ~~common stock issued for services, with notes payable arrangements in connection with note extension agreements, and~~the Company’s derivative liability which generated an income from the change of fair value of $11.4 million as ~~repayment for outstanding debts, in estimating the useful life used for depreciation and amortization~~opposed to an expense of ~~our long-lived assets,~~$1.9 million in the ~~valuation of the derivative liability, and the valuation of deferred income tax assets. Actual results and outcomes may differ from management's estimates and assumptions.~~

~~Recently Issued Accounting Pronouncements~~

We anticipate continued large fluctuations in other income/expense as a going concern within one year after the date that financial statements are issued. Substantial doubt is defined as an indication that it is probable that an entity will be unable to meet its obligations as they become due within one year after the date that financial statements are issued. If management has concluded that substantial doubt exists, then the following disclosures should be made in the financial statements: (i) principal conditions or events that raised the substantial doubt, (ii) management’s evaluation of the significance of those conditions or events in relation to the entity’s ability to meet its obligations, (iii) management’s plans that alleviated the initial substantial doubt or, if substantial doubt was not alleviated, management’s plans that are intended to at least mitigate the conditions or events that raise substantial doubt, and (iv) if the latter in (iii) is disclosed, an explicit statement that there is substantial doubt about the entity’s ability to continue as a going concern. These changes became effective for the Company for the 2016 annual period. Management has evaluated the impact of the adoption of these changes and has determined there will be no material impact on the consolidated financial statements. Subsequent to adoption, this guidance will need to be applied by management at the end of each annual period and interim period therein to determine what, if any, impact there will be on the consolidated financial statements in a given reporting period.

In April 2015, the FASB issued ASU No 2015-3, Simplifying the Presentation of Debt Issuance Costs. This update changes the presentation of debt issuance costs in the balance sheet. ASU 2015-03 requires debt issuance costs related to a recognized debt obligation to be presented in the balance sheet as a direct deduction from the carrying amount of the related debt liability rather than being presented as an asset. Amortization of debt issuance costs will continue to be reported as interest expense. In August 2015, the FASB issued ASU 2015-15, “Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements”. This ASU clarified guidance in ASC 2015-03 stating that the SEC staff would not object to a company presenting debt issuance costs related to a line-of-credit arrangement on the balance sheet as a deferred asset, regardless of whether there were any outstanding borrowings at period-end. This update is effective for annual and interim periods beginning after December 15, 2015, which required us to adopt these provisions in the first quarter of 2016. This update was applied on a retrospective basis, wherein the balance sheet of each period presented was adjusted to reflect the effects of applying the new guidance. The adoption of this guidance did not have a material impact on our consolidated financial statements.

In November 2015, the FASB issued ASU No 2015-17, Income Taxes (Topic 740). The amendments in ASU 2015-17 change the requirements for the classification of deferred taxes on the balance sheet. Currently, GAAP requires an entity to separate deferred income tax liabilities and assets into current and noncurrent amounts in a classified statement of financial position. To simplify the presentation of deferred income taxes, the amendments in this ASU require that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. The pronouncement is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2016. Earlier application is permitted for all entities as of the beginning of an interim or annual reporting period. The Company has early adopted this pronouncement for the fiscal reporting period ended December 31, 2016, and has reclassified the presentation of deferred income taxes in the prior period to conform to the current year classification in the consolidated balance sheets. As a result of ~~the Company having recognized a valuation reserve for the entire deferred tax liability balance at September 30, 2017 and December 31, 2016, there is no impact~~quarterly re-evaluation of the ~~presentation of deferred income taxes in our financial statements.~~Company’s derivative liabilities.

~~The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements.~~

~~Results of Operations~~

Three Months ended September 30, ~~2017~~2023, and ~~2016~~2022:

Three Months Ended September 30, Favorable
2017 2016 (Unfavorable) %

Operating expenses $ 1,035,628 $ 1,310,748 $ 275,120 -21.0 %

Loss from operations (1,035,628 ) (1,310,748 ) 275,120 -21.0 %

Other income (expense) (5,636,476 ) (908,093 ) (4,728,383 ) 520.7 %

Net income (loss) $ (6,672,104 ) $ (2,218,841 ) $ (4,453,263 ) 200.7 %

	Three Months Ended September 30,						Favorable
	2023			2022			(Unfavorable)			%

Revenue	$	1,520		$	10,960		$	(9,440	)		(86)	%
Cost of revenue		827			4,027			3,200			79	%
Gross profit		693			6,933			(6,240	)		(90)	%

Operating expenses		473,490			503,711			30,221			6	%

Loss from operations		(472,797	)		(496,778	)		23,981			5	%

Other income (expense)		(293,373	)		(106,582	)		(186,791)			(175	)%

Net gain/loss	$	(766,170	)	$	(603,360	)	$	162,810			27	%

Revenue

Revenue of the Company’s SofPulse® product during the three months ended September 30, 2023, was $1,520, a decrease of $9,440, or 86%, compared to $10,960 for the three months ended September 30, 2022.

Cost of Revenue

Cost of revenue during the three months ended September 30, 2023, was $827, a decrease of $3,200 or 80% compared to $4,027 for the three months ended September 30, 2022. Cost of revenue is recognized on those sales recorded as gross for which we are the principal in the transaction as opposed to net sales which reflect no cost of revenue. It is anticipated that cost of revenue will increase in future quarters as the roll out of the SofPulse® product continues.

Operating Expenses

~~Our operating~~Operating expenses decreased by $30,221 or 6%, to $473,490 for the three months ended September 30, 2023, compared to $503,711 for the three months ended September 30, 2022.

Other Income (Expense)

Other expenses for the three months ended September 30, ~~2017 were approximately $1,035,628~~2023, was $293,373 compared to ~~$1,310,748~~other expense of $106,582 for the corresponding period of the previous year. The operating expenses were comprised primarily from consulting and professional fees for the development of our intellectual property and expenses related to being a public company. A significant portion of these fees were paid for with the issuance of restricted shares of common stock. During the three months ended September 30, 2017, 576,660 shares of common stock were issued for consulting services valued at $15,720 as compared to 4,513,514 shares of common stock being issued for consulting services valued at $663,519, during the corresponding period of the previous year.2022.

~~Other Income (Expense)~~

Other income (expense) for the quarter ended September 30, 2017 was expense of $5,636,476 compared to expense of $908,093 for the quarter ended September 30, 2016. This change was due primarily to a change in valuation of our derivative liabilities and net of interest expense resulting from the amortization of the discounts on notes payable. In addition, we had a loss on extinguishment of debt of $58,197 during the quarter ended September 30, 2017 compared to a loss of $42,507 during the quarter ended September 30, 2016. We anticipate continued large fluctuations in other income (expense) as a result of quarterly re-evaluation of these derivative liabilities.

~~Nine months ended September 30, 2017 and 2016~~

Nine Months Ended September 30, Favorable
2017 2016 (Unfavorable) %

Operating expenses $ 3,770,929 $ 4,778,109 $ 1,007,180 21.1 %

Loss from operations (3,770,929 ) (4,778,109 ) 1,007,180 21.1 %

Other income (expense) (8,808,162 ) 202,268 (9,010,430 ) NM

Net loss $ (12,579,091 ) $ (4,575,841 ) $ (8,003,250 ) -174.9 %

~~Operating Expenses~~

Our operating expenses for the nine months ended September 30, 2017 were approximately $3,770,929 compared to $4,778,109 for the corresponding period of the previous year. The operating expenses were comprised primarily from consulting and professional fees for the development of our intellectual property and expenses related to being a public company. A significant portion of these fees were paid for with the issuance of restricted shares of common stock. During the nine months ended September 30, 2017, 3,598,996 shares of common stock were issued for consulting services valued at $199,555 as compared to 9,346,760 shares of common stock being issued for consulting services valued at $2,291,373, during the corresponding period of the previous year. Also, during the nine months ended September 30, 2107 the company issued stock options valued at $1,139,403 to independent contractors.

~~Other Income (Expense)~~

Other income (expense) for the nine months ended September 30, 2017 was expense of $8,808,162 compared to income of $202,268 for the nine months ended September 30, 2016. This change was due primarily to a change in valuation of our derivative liabilities and net of interest expense resulting from the amortization of the discounts on notes payable. In addition, we had income on extinguishment of debt of $2,175,459 during the nine months ended September 30, 2017 compared to a loss of $435,625 during the nine months ended September 30, 2016. We anticipate continued large fluctuations in other income (expense) as a result of quarterly re-evaluation of these derivative liabilities.

Liquidity and Capital Resources

	As of						Favorable			As of
	September 30, 2017			December 31, 2016			(Unfavorable)			September 30, 2023			December 31, 2022			Favorable (Unfavorable)
Working Capital

Current assets	$	155,479		$	302,854		$	(147,375	)	$	35,504		$	15,822		$	19,682
Current liabilities		13,189,069			8,721,324			(4,467,745	)		23,696,070			33,381,760			9, 685,690
Working capital deficit	$	(13,033,590	)	$	(8,418,470	)	$	(4,615,120	)	$	(23,660,566	)	$	(33,365,938	)	$	9,705,372

Long-term debt	$	155,000		$	159,221		$	4,221		$	79,825		$	79,825		$	-

Stockholders' deficit	$	(13,183,836	)	$	(8,561,866	)	$	(4,621,970	)

Shareholders’ deficit										$	(22,960,131	)	$	(32,180,319	)	$	9,220,188

Nine Months Ended September 30, Favorable
2017 2016 (Unfavorable)
Statements of Cash Flows Select Information

Net cash provided (used) by:
Operating activities $ (2,189,196 ) $ (1,803,684 ) $ (385,512 )
Investing activities $ - $ - $ -
Financing activities $ 2,198,142 $ 1,856,886 $ 341,256

As of Favorable
September 30, 2017 December 31, 2016 (Unfavorable)
Balance Sheet Select Information

Cash $ 64,479 $ 55,533 $ 8,946

Accounts payable and accrued expenses $ 3,238,237 $ 4,727,247 $ 1,489,010

	Nine Months Ended September 30,						Favorable
	2023			2022			(Unfavorable)
Statements of Cash Flows Select Information

Net cash provided (used) by:
Operating activities	$	(404,363	)	$	(329,436	)	$	(74,829	)
Financing activities	$	404,265		$	243,500		$	160,765

	As of
	September 30, 2023		December 31, 2022		Favorable (Unfavorable)
Balance Sheet Select Information

Cash	$	-	$	98	$	98

Accounts payable and accrued expenses	$	10,736,269	$	8,869,451	$	(1,866,818	)

Since ~~inception~~January 1, 2023, and through September 30, ~~2017,~~2023, the Company has raised approximately ~~$7.8~~$0.5 million in equity and debt transactions. These funds have been used ~~for the operations of the Company~~ to ~~acquire and the development of its intellectual property portfolio. These activities include attending trade shows and~~fund on-going corporate ~~development.~~operations. Our accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for the ~~twelve month~~twelve-month period following the date of these condensed consolidated financial statements. Our cash on hand at September 30, 2023 was approximately $0. The Company has incurred substantial losses since its inception. Its current liabilities exceed its current assets and available cash is not sufficient to fund expected future operations. The Company is contemplating raising additional capital through debt and equity ~~securities~~ in order to continue the funding of its ~~operations.~~operations and to acquire a profitable business. However, there is no assurance that the Company can raise ~~enough~~sufficient funds or generate sufficient revenues to pay its obligations as they become due, which raises substantial doubt about our ability to continue as a going concern. To reduce the risk of not being able to continue as a going concern, management has implemented its business plan to materialize revenues from potential, future, license agreements and has initiated a private placement offering to raise capital through the sale of its common stock. In addition, management has a commitment from a current lender for a total of $2.7 million in the form of convertible notes. As of September 30, 2017, the Company has received cash funding of $1,562,000 for $1,667,500 of convertible notes under this commitment. This commitment is subject to the Company not taking any variable financing from any other investor or lender. Although, uncertainty exists as to whether the Company will be able to generate enough cash from operations to fund the Company’s working capital needs or raise sufficient capital to meet the Company’s obligations as they become due, no adjustments have been made to the carrying value of assets or liabilities as a result of this uncertainty. Our cash on hand at September 30, 2017 was approximately $64,479. This will be insufficient to fund operations if additional capital is not raised. The Company raised an aggregate of approximately $2,302,000 through the sale of equity and debt securities during the nine months ended September 30, 2017.

The Company is not aware of any recently issued accounting pronouncements that when adopted will have a material effect on the Company’s financial position or ~~result~~results of its ~~operation.~~operations.

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements.

Item 3. Quantitative and Qualitative Disclosures about Market Risk.

We are a Smaller Reporting Company and are not required to provide the information under this item.

Item 4. Controls and Procedures.

Disclosure of controls and procedures.

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports, filed under the Securities Exchange Act of 1934, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable and not absolute assurance of achieving the desired control objectives. In reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. In addition, the design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, a control may become inadequate because of changes in conditions or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

As required by the SEC Rule 13a-15(b), we carried out an evaluation under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based on the foregoing, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were not effective at ~~the~~a reasonable assurance level due to the material weaknesses described below.

In light of the material weaknesses described below, we performed additional analysis and other post-closing procedures to ensure our financial statements were prepared in accordance with generally accepted accounting principles. Accordingly, we believe that the financial statements included in this report fairly present, in all material respects, our financial condition, results of operations and cash flows for the periods presented.

A material weakness is a control deficiency (within the meaning of the Public Company Accounting Oversight Board (PCAOB) Auditing Standard No. 2) or combination of control deficiencies that result in more than a remote likelihood that a material misstatement of the annual or interim financial statements will not be prevented or detected.

Management has identified the following two material weaknesses which have caused management to conclude that as of September 30, ~~2017~~2023, our disclosure controls and procedures were not effective at the reasonable assurance level:

1. We do not have written documentation of our internal control policies and procedures. Written documentation of key internal controls over financial reporting is a requirement of Section 404 of the Sarbanes-Oxley Act, which is applicable to us for the quarter ended September 30, ~~2017.~~2023. Management evaluated the impact of our failure to have written documentation of our internal controls and procedures on our assessment of our disclosure controls and procedures and has concluded that the control deficiency that resulted represented a material weakness.

2. We do not have sufficient segregation of duties within accounting functions, which is a basic internal control. Due to our size and nature, segregation of all conflicting duties may not always be possible and may not be economically feasible. However, to the extent possible, the ~~initiation~~authorization of transactions, the custody of assets and the recording of transactions should be performed by separate individuals. The recording of transactions function is maintained by a third-party consulting firm whereas authorization and custody remains under the Company’s Chief Executive Officer’s responsibility. Management evaluated the impact of our failure to have segregation of duties on our assessment of our disclosure controls and procedures and has concluded that the control deficiency that resulted represented a material weakness.

To address these material weaknesses, management performed additional analyses and other procedures to ensure that the financial statements included herein fairly present, in all material respects, our financial position, results of operations and cash flows for the periods presented.

Changes in internal controls over financial reporting.

There has been no change in our internal control over financial reporting that occurred during the fiscal quarter covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

Item 1. Legal Proceedings.

~~We are~~The Company is subject to certain legal proceedings, which it considers routine to its business activities. As of September 30, 2023, the Company believes, after consultation with legal counsel, that the ultimate outcome of such legal proceedings, whether individually or in the aggregate, is not ~~currently involved in any litigation that we believe could~~likely to have a material adverse effect on ~~our~~the Company’s financial ~~condition or~~position, results of ~~operations. There is no action, suit, proceeding, inquiry~~operations or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of our company or any of our subsidiaries, threatened against or affecting our company, our common stock, any of our subsidiaries or of our companies or our subsidiaries’ officers or directors in their capacities as such, in which an adverse decision could have a material adverse effect. Notwithstanding the foregoing, a consultant has commenced litigation against us, which is in the early stages. We anticipate that these matters will be settled, however, if a settlement cannot be reached, we will vigorously defend these matters and we do not believe that there will be any material adverse effect as a result thereof, but there is always uncertainty in any litigation and a result cannot be guaranteed.liquidity.

Item 1A. Risk Factors.

We are a ~~Smaller Reporting Company~~smaller reporting company (as defined in Rule 12b-2 of the Exchange Act) and are not required to provide the information under this item.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

Number of	Number of
Common Shares	Common Shares	Source of			Source of
Issued	Issued	Payment	Amount		Payment	Amount
	576,660	Services	$	15,720
	12,500	Note extension	$	386
	12,655,161	Cash	$	255,000
	23,024,976	Conversion of notes	$	660,743
	3,625,000	Settlement of Liabilities	$	103,730
10,900,000					Conversion of notes and accrued interest	$	109,000
4,300,590					Settlement of debt		67,089
1,667,000					Settlement of deferred compensation		24,338
5,000,000					Conversion preferred stock		-
27,500,000					Cash		460,000
1,507,277					Make good provision		24,870
43,800,000					Shares for services		720,562
1,850,000					Commitment shares		25,625
1,000,000					Note Extension Agreements		11,130
8,000,000					Production Agreement		112,800

The above issuances of securities during the ~~three~~nine months ended September 30, ~~2017~~2023, were exempt from registration pursuant to Section 4(2), and/or Regulation D promulgated under the Securities Act. These securities qualified for exemption under Section 4(2) of the Securities Act since the issuance of these securities by us did not involve a public offering. The offering was not a “public offering” as defined in Section 4(2) due to the insubstantial number of persons involved in the deal, size of the offering, manner of the offering and number of securities offered. We did not undertake an offering in which we sold a high number of securities to a high number of investors. In addition, these stockholders had the necessary investment intent as required by Section 4(2) since they agreed to and received share certificates bearing a legend stating that such securities are restricted pursuant to Rule 144 of the Securities Act. This restriction ensures that these securities would not be immediately redistributed into the market and therefore not be part of a “public offering.” Based on an analysis of the above factors, we have met the requirements to qualify for exemption under Section 4(2) of the Securities Act for this transaction.

Item 3. Defaults upon Senior Securities.

None

Item 4. Mine Safety Disclosures.

Not applicable

Item 5. Other Information

None

I~~tem~~Item 6. Exhibits

(a) Exhibits

Exhibit Number		Exhibit Title

~~31.1~~31.1*		Certification of Principal Executive Officer and Principal Financial Officer, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

~~32.1~~32.1*		Certification of Principal Executive Officer and Principal Financial Officer, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101*		Inline XBRL Document set for the financial statements and accompanying notes in Part I, Item 1, of this Quarterly Report on Form 10-Q

104*		Inline XBRL for the cover page of this Quarterly Report on Form 10-Q, included in the Exhibit 101 Inline XBRL Document Set.

		Exhibits designated by the symbol * are filed or furnished with this Quarterly Report on Form 10-Q


101.INS *		~~XBRL Instance Document~~

101.SCH *		~~XBRL Taxonomy Schema~~

101.CAL *		~~XBRL Taxonomy Calculation Linkbase~~

101.DEF *		~~XBRL Taxonomy Definition Linkbase~~

101.LAB *		~~XBRL Taxonomy Label Linkbase~~

101.PRE *		~~XBRL Taxonomy Presentation Linkbase~~

~~In accordance with SEC Release 33-8238, Exhibit 32.1 and 32.2 are being furnished and not filed.~~

* Furnished herewith. XBRL (Extensible Business Reporting Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.SIGNATURES

~~SIGNATURES~~

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: ~~November 7, 2017~~December 28, 2023	Endonovo Therapeutics, Inc.

	By:	/s/ Alan Collier
		Alan Collier
		Chief Executive Officer
		(Duly Authorized Officer, Principal Executive Officer, and Principal Financial Officer)

	September 30,			December 31,
	2017			2016
	(Unaudited)			(Audited)

ASSETS
Current assets:
Cash	$	64,479		$	55,533
Prepaid expenses and other current assets		91,000			247,321
Total current assets		155,479			302,854

Property Plant and Equipment, net		4,754			15,825

Total assets	$	160,233		$	318,679

LIABILITIES AND SHAREHOLDERS' DEFICIT
Current Liabilities
Accounts payable and accrued expenses	$	3,238,237		$	4,727,247
Short term advances		6,973			5,823
Notes payable, net of discounts of $920,773 as of September 30, 2017 and $1,145,849 as of December 31, 2016		2,549,445			1,878,107
Notes payable - related parties		170,000			170,000
Derivative liability		7,217,059			1,927,752
Current portion of long term loan		7,355			12,395

Total current liabilities		13,189,069			8,721,324

Long term loan		-			4,221
Acquisition payable		155,000			155,000
Total liabilities		13,344,069			8,880,545
COMMITMENTS AND CONTINGENCIES
Shareholders' deficit
Super AA super voting preferred stock, $0.001 par value; 1,000,000 authorized and 5,000 and 1,000 issued and outstanding at September 30, 2017 and December 31, 2016		5			-
Series B convertible preferred stock, $0.0001 par value; 50,000 shares authorized, 0 shares issued and outstanding at September 30, 2017 and December 31, 2016		-			-
Common stock, $.0001 par value; 500,000,000 shares authorized; 284,063,508 and 134,336,637 shares issued and outstanding as of September 30, 2017 and December 31, 2016		28,404			13,434
Additional paid-in capital		17,755,199			9,800,553
Stock subscriptions		(14,070	)		(1,570	)
Accumulated deficit		(30,953,374	)		(18,374,283	)
Total shareholders' deficit		(13,183,836	)		(8,561,866	)
Total liabilities and shareholders' deficit	$	160,233		$	318,679

	Series AA Preferred Stock				Series B Convertible Preferred Stock				Common Stock				Additional Paid-in		Common Stock Subscription			Retained			Total Shareholder's
	Shares		Amount		Shares		Amount		Shares		Amount		Capital		Receivable			Earnings			Deficit

Balance December 31, 2016		1,000	$	-		-	$	-		134,336,637	$	13,434	$	9,800,553	$	(1,570	)	$	(18,374,283	)	$	(8,561,866	)

Private placement units issued for cash		-		-		-		-		28,830,028		2,882		737,368		(12,500	)		-			727,750
Preferred stock issued for cash		4,000		5		-		-		-		-		-		-			-			5
Shares issued for services		-		-		-		-		3,598,996		359		199,196		-			-			199,555
Shares issued with lock-up agreements		-		-		-		-		126,618		13		7,517		-			-			7,530
Shares issued for conversion of notes payable and accrued interest		-		-		-		-		106,110,372		10,610		3,977,803		-			-			3,988,413
Private placement units issued for conversion of notes payable and accrued interest		-		-		-		-		3,370,041		337		66,029		-			-			66,366
Shares issued related to debt extinguishment		-		-		-		-		1,565,816		156		86,838		-			-			86,994
Shares issued for repayment of accrued liabiity		-		-		-		-		6,125,000		613		202,068		-			-			202,681
Valuation of stock options issued for servces		-		-		-		-		-		-		1,139,403		-			-			1,139,403
Valuation of warrants issued for services		-		-		-		-		-		-		71,113		-			-			71,113
Valuation of stock options issued in exchange of deferred compensation		-		-		-		-		-		-		1,467,311		-			-			1,467,311
Net loss for the period ended September 30, 2017		-		-		-		-		-		-		-		-			(12,579,091	)		(12,579,091	)
Balance September 30, 2017		5,000	$	5		-	$	-		284,063,508	$	28,404	$	17,755,199	$	(14,070	)	$	(30,953,374	)	$	(13,183,836	)

	Notes to
12 months ending,	Related parties		Non-related parties		Total

September 30, 2018	$	170,000	$	3,470,218	$	3,640,218
	$	170,000	$	3,470,218	$	3,640,218

Twelve months ending,
September 30, 2018	$	7,355
	$	7,355

Current portion	$	7,355
Long term portion	$	-

	Outstanding Warrants
			Weighted Average
			Exercise Price
	Shares		Per Share
Outstanding at January 1, 2017		9,494,940	$	0.33
Granted		33,300,747	$	0.24
Cancelled		-	$	-
Exercised		-	$	-
Outstanding at September 30, 2017		42,795,687	$	0.26

Exercisable at September 30, 2017		42,795,687	$	0.26

	Fair Value Measurements Using
	Quoted Prices in		Significant Other		Significant
	Active Markets for		Observable		Unobservable
		Identical Assets		Inputs		Inputs
		(Level 1)		(Level 2)		(Level 3)		Total

As of September 30, 2017
Derivative liability	$	-	$	-	$	7,217,059	$	7,217,059
Total	$	-	$	-	$	7,217,059	$	7,217,059